"EFFECT OF URSODEOXYCHOLIC ACID IN UNCONJUGATED HYPERBILIRUBINEMIA IN

THE TERM NEONATES TREATED WITH PHOTOTHERAPY."

By

DR. CHINTHAPUVU VIVEK

Dissertation submitted to the B.L.D.E. (DEEMED TO BE UNIVERSITY) VIJAYAPURA, KARNATAKA



In Partial fulfilment of requirements for the degree of

MASTER OF MEDICINE

In

PAEDIATRICS

Under the guidance of

PROF. (DR.). R. H. GOBBUR PROFESSOR DEPARTMENT OF PAEDIATRICS & DR SHRISHAIL M GIDAGANTI , MD DEPARTMENT OF PAEDIATRICS

B.L.D.E. (DEEMED TO BE UNIVERSITY)

Shri B.M. Patil Medical College Hospital and Research Centre

Vijayapura, Karnataka – 586103

2022 - 2025



Declaration by the candidate

I, DR.CHINTHAPUVU VIVEK, hereby declare that this dissertation/thesis entitled URSODEOXYCHOLIC *"EFFECT* OF ACID IN UNCONJUGATED **HYPERBILIRUBINEMIA** IN THE TERM NEONATES TREATED WITH **PHOTOTHERAPY**" is a bonafide and genuine research work carried out by me under the guidance of R. H. GOBBUR MD Professor, Department of Paediatrics B.L.D.E (DU)'s Shri B.M Patil Medical College, Hospital and Research Centre, Vijayapura.

Date:

Place: Vijayapura Postgraduate

DR. CHINTHAPUVU VIVEK

Department of PAEDIATRICS B.L.D.E. (Deemed to be University) Shri B.M. Patil Medical College Hospital and Research Centre Vijayapura, Karnataka



Certificate by the Guide

This is to certify that the dissertation entitled "EFFECT OF URSODEOXYCHOLIC ACID IN UNCONJUGATED HYPERBILIRUBINEMIA IN THE TERM NEONATES TREATED WITH PHOTOTHERAPY" is a bonafide and genuine research work carried out by Dr. CHINTHAPUVU VIVEK under my overall supervision and guidance in partial fulfilment of the requirement for the degree of M.D. in Paediatrics B.L.D.E (DU)'s Shri B.M Patil Medical College, Hospital and Research Centre, Vijayapura.

Date:

Place: Vijayapura

DR. R. H. GOBBUR

Professor Department Of PAEDIATRICS Department of B.L.D.E. (Deemed to be University) Shri B.M. Patil Medical College Hospital and Research Centre Vijayapura, Karnataka



<u>Certificate by the Co-Guide</u>

This is to certify that the dissertation entitled "EFFECT OF URSODEOXYCHOLIC ACID IN UNCONJUGATED HYPERBILIRUBINEMIA IN THE TERM NEONATES TREATED WITH PHOTOTHERAPY" is a bonafide and genuine research work carried out by Dr. CHINTHAPUVU VIVEK under my overall supervision and guidance in partial fulfilment of the requirement for the degree of M.D. in Paediatrics B.L.D.E (DU)'s Shri B.M Patil Medical College, Hospital and Research Centre, Vijayapura.

Date:

Place: Vijayapura

Dr S M GIDAGANTI

Asst Professor Department Of PAEDIATRICS Department of B.L.D.E. (Deemed to be University) Shri B.M. Patil Medical College Hospital and Research Centre Vijayapura, Karnataka



Endorsement by the Head of Department

This is to certify that the dissertation entitled "EFFECT OF URSODEOXYCHOLIC ACID IN UNCONJUGATED HYPERBILIRUBINEMIA IN THE TERM NEONATES TREATED WITH PHOTOTHERAPY" is a bonafide and genuine research work carried out by DR.CHINTHAPUVU VIVEK under the guidance of MBBS, MS, DOMS, PhD (Medical) Professor and Head, Department of PAEDIATRICS B.L.D.E (DU)'s Shri B.M Patil Medical College, Hospital and Research Centre, Vijayapura.

Date: Place: Vijayapura

> Prof. (Dr.) M.M Patil MBBS, MD

Professor and head Department of PEADIATRICS B.L.D.E. (Deemed to be University) Shri B.M. Patil Medical College Hospital and Research Centre Vijayapura, Karnataka



Endorsement by the Principal / Head of the Institution

This is to certify that the dissertation entitled "EFFECT OF URSODEOXYCHOLIC ACID IN UNCONJUGATED HYPERBILIRUBINEMIA IN THE TERM NEONATES TREATED WITH PHOTOTHERAPY" is a bonafide and genuine research work carried out by DR.CHINTHAPUVU VIVEK under the guidance of Prof. (Dr.) R. H. GOBBUR SIR MBBS, MD Professor, Department of PAEDIATRICS B.L.D.E (DU)'s Shri B.M Patil Medical College, Hospital and Research Centre, Vijayapura

Date

Place: Vijayapura

Prof. (Dr.) Aravind V. Patil MS (Surgery)

Principal

B.L.D.E. (Deemed to be University) Shri B.M. Patil Medical College Hospital and Research Centre Vijayapura, Karnataka



COPYRIGHT Declaration by the candidate

I hereby declare that the BLDE (Deemed to be University), Vijayapura, Karnataka shall have the rights to preserve, use and disseminate this dissertation/thesis titled "EFFECT OF URSODEOXYCHOLIC ACID IN UNCONJUGATED HYPERBILIRUBINEMIA IN THE TERM NEONATES TREATED WITH PHOTOTHERAPY" in print or electronic format for academic/research purpose..

Date:

Place: Vijayapura

DR.CHINTHAPUVU VIVEK

Postgraduate

Department of PEADIATRICS B.L.D.E. (Deemed to be University) Shri B.M. Patil Medical College Hospital and Research Centre Vijayapura, Karnataka

© B.L.D.E (Deemed to be University), Vijayapura, Karnataka

~ v ~

ACKNOWLEDGEMENT

With a humble heart, I would like to begin this acknowledgement with a prayer to the Almighty God, who has given us the strength, wisdom, and grace to embark on this scholarly journey.

I am profoundly grateful to my teacher, mentor and guide, **Prof. (Dr.) R. H. GOBBUR SIR**, whose unwavering inspiration, encouragement, and support have been instrumental throughout my post-graduation studies and the preparation of my dissertation. Her guidance has been invaluable, and I deeply appreciate her dedication to my academic and professional growth.

I am deeply indebted to my esteemed Professors, **Dr. MM patil sir,Dr.Ss Kalyanshetter sir** and **Dr.SV Patil sir** whose guidance and encouragement have propelled me to new heights of professional achievement throughout my course. Their mentorship has been instrumental in shaping my academic journey, and I am forever grateful for their invaluable support and inspiration.

My heartfelt thanks and deep gratitude to my teachers, **Dr. Shrishail** gidaganti, **Dr. Siddu charki, Dr. Vijay birader** and **Dr. Pooja V**. Without their inspiration, timely guidance, immense support, and motivation, I wouldn't have been able to complete this dissertation.

I am grateful to **Dr. Aravind V Patil**, Principal of BLDE (DU) 's Shri B. M Patil Medical College Hospital and Research Centre, Vijayapura, for permitting me to utilise the resources in the completion of my work. I am extremely thankful to **Mr. Muragesh Mathapati** for his guidance in statistical analysis. I thank my friends and colleagues specially **Dr. Vaishnavi B,Dr. Manasi S,Dr.Mahesh K** and **Dr. Ruchi R.** for their constant support.

I express my heartfelt appreciation and gratitude to my beloved parents, *Mr.Ravinder Ch* and *Mrs.Vanaja* and my beloved brother *Shravan kumar* for their support, invaluable advice, and endless encouragement. Their boundless love and sacrifices have been the cornerstone of my journey, and I am deeply indebted to them for instilling in me the values of perseverance and determination.

Finally, I acknowledge my heartfelt gratitude to all my patients; this study would be incomplete without their participation.

DR.CHINTHAPUVU VIVEK

Postgraduate

Department of Pediatrics B.L.D.E. (Deemed to be University) Shri B.M. Patil Medical College Hospital and Research Centre Vijayapura, Karn

LIST OF CONTENTS

Sl. no	Particulars	Page no.
1.	Abstract &Introduction	1-6
2.	Aim and Objectives	7
3.	Review of literature	8-28
4.	Materials and methods	29-32
5.	Results	33-40
6.	Discussion	41-44
7.	Summary	44
8.	Limitations	45
9.	Conclusion	45
10.	References	46-51
11.	Appendix I: Consent form	52-60
	Appendix II: Case proforma	
	Appendix III: Institutional ethical clearance	
	Appendix IV: Master chart	
	Appendix V: Plagiarism report	

ABBREVIATIONS

S. No.	Abbreviation	Full Form
1	UDCA	Ursodeoxycholic Acid
2	PT	Phototherapy
3	UCHB	Unconjugated Hyperbilirubinemia
4	TSB	Total Serum Bilirubin
5	UCB	Unconjugated Bilirubin
6	NICU	Neonatal Intensive Care Unit
7	ABE	Acute Bilirubin Encephalopathy
8	BIND	Bilirubin-Induced Neurologic Dysfunction
9	LED	Light Emitting Diode
10	NVD	Normal Vaginal Delivery
11	LSCS	Lower Segment Caesarean Section
12	APGAR	Appearance, Pulse, Grimace, Activity, Respiration
13	G6PD	Glucose-6-Phosphate Dehydrogenase
14	Hb	Hemoglobin
15	UGT1A1	Uridine Diphosphate-Glucuronosyltransferase 1A1
16	RES	Reticuloendothelial System
17	ET	Exchange Transfusion
18	BSEP	Bile Salt Export Pump
19	MRP2	Multidrug Resistance-associated Protein 2
20	SPSS	Statistical Package for the Social Sciences



LIST OF TABLES

S. No.	Title	Page No.
1	Baseline Characteristics of the Study Population	32
2	Clinical Parameters at Admission	34
3	Serial Bilirubin Measurements	36
4	Impact on Phototherapy and NICU Stay	37
5	Safety and Adverse Effects of UDCA	38

LIST OF GRAPHS

S. No.	Title	Page No.
1	Bar Graph of Baseline Characteristics	33
2	Line Graph of Mode of Delivery Distribution	33
3	Bar Graph of Neonatal Gender Distribution	34
4	Line Graph of Clinical Parameters at Admission	35
5	Bar Graph of TSB and UCB Levels	37
6	Bar Graph of Phototherapy Duration and NICU Stay	38
7	Bar Graph of Safety and Adverse Effects of UDCA	39

LIST OF FIGURES

S. No.	Title	Page No.
1	Figure: Pathophysiology of Bilirubin Metabolism (Tsai MT et al., 2018)	11
2	Figure: Complications of Unconjugated Neonatal Hyperbilirubinemia and BIND (Amin P., 2018)	13

ABSTRACT

Background

Neonatal hyperbilirubinemia affects 60-80% of term neonates in the first week of life, with phototherapy (PT) being the standard treatment. However, prolonged PT has limitations, leading to the exploration of adjuvant therapies such as Ursodeoxycholic Acid (UDCA) to enhance bilirubin clearance.

Objective

To evaluate the efficacy and safety of UDCA as an adjunct to PT in term neonates with unconjugated hyperbilirubinemia (UCHB) by comparing bilirubin reduction, phototherapy duration, and hospital stay between neonates receiving UDCA + PT versus PT alone.

Methods

A randomized controlled study was conducted on 100 term neonates, divided into:

- Group 1 (UDCA + PT, n = 50) receiving oral UDCA (10–15 mg/kg/day) with PT.
- Group 2 (PT-only, n = 50) receiving standard PT alone.

Total serum bilirubin (TSB) levels were measured at admission, 24 hours, and 48 hours. Phototherapy duration, NICU stay, and adverse effects were analyzed. Statistical analysis was performed using SPSS software, with p < 0.05 considered significant.

Results

The baseline characteristics were comparable between both groups (p > 0.05). The TSB decline at 48 hours was 9.3 ± 1.75 mg/dL in the UDCA + PT group versus 9.8 ± 1.9 mg/dL in the PT-only group (p = 0.175). The mean phototherapy duration was 47.84 ± 2.5 hours in the UDCA group and 48.22 ± 5.5 hours in the control group (p = 0.66). The mean NICU stay was 3.02 ± 0.24 days in the UDCA group and 3.0 ± 0.2 days in the PT-only group (p = 0.651).UDCA was well tolerated,

with only 3 neonates experiencing mild vomiting, and no cases of diarrhea or metabolic disturbances reported.

Conclusion

UDCA may modestly enhance bilirubin clearance, but the observed differences in bilirubin reduction, phototherapy duration, and NICU stay were not statistically significant. Given its favorable safety profile, further large-scale randomized controlled trials (RCTs) are needed to confirm UDCA's role as a routine adjunct in neonates.

INTRODUCTION

Neonatal **unconjugated hyperbilirubinemia** (**UH**) is a widespread condition affecting approximately **60-80% of term neonates** and an even higher percentage of **preterm infants** during the first week of life¹. The accumulation of **unconjugated bilirubin** (**UCB**) in the bloodstream leads to **jaundice**, which manifests as a yellow discolouration of the skin and sclerae. While neonatal jaundice is often **physiological** and self-resolving, it can progress to **severe hyperbilirubinemia** (**TSB** > **20 mg/dL**), increasing the risk of **acute bilirubin encephalopathy** (**ABE**) and **kernicterus**, both of which can cause **irreversible neurological damage**². Given these risks, **timely and effective management** of hyperbilirubinemia is critical to preventing long-term complications.

The pathophysiology of **neonatal jaundice** involves several mechanisms. First, newborns experience **increased bilirubin production** due to the **shorter lifespan of fetal erythrocytes** (70-90 days, compared to 120 days in adults)³. Additionally, the neonatal liver has **immature conjugation abilities** due to the **low activity of uridine diphosphate-glucuronosyltransferase** (**UGT1A1**), the enzyme responsible for bilirubin conjugation⁴. Furthermore, **increased enterohepatic circulation** due to high levels of β -glucuronidase in the neonatal gut facilitates the **reabsorption of bilirubin**, leading to prolonged jaundice⁵. While most cases of neonatal hyperbilirubinemia resolve spontaneously, some neonates develop **severe hyperbilirubinemia** requiring medical intervention.

The American Academy of Pediatrics (AAP) recommends phototherapy (PT) as the primary treatment for neonatal UH⁶. Phototherapy effectively lowers serum bilirubin levels by converting UCB into water-soluble isomers, which are excreted via bile and urine. Despite its

effectiveness, prolonged PT is associated with several complications, including dehydration, electrolyte imbalances, thermal instability, retinal damage, oxidative stress, and disruption of maternal-infant bonding⁷. In severe cases, exchange transfusion is required, but this procedure carries significant risks such as hemodynamic instability, infections, thrombocytopenia, and necrotizing enterocolitis (NEC)⁸. These limitations have prompted researchers to explore adjuvant therapies that could enhance bilirubin clearance and reduce the duration of phototherapy.

Historical aspect:

Over the years, various pharmacological agents have been investigated for managing neonatal hyperbilirubinemia. **Phenobarbital**, an enzyme inducer, has been used to enhance bilirubin conjugation but is associated with **neurological side effects** like **sedation**⁹. **Clofibrate**, a peroxisome proliferator-activated receptor (PPAR) agonist, has been shown to increase bilirubin conjugation, but its **long-term safety in neonates remains unclear**¹⁰. **D-penicillamine**, a metal chelator that binds bilirubin, has shown **limited efficacy**¹¹. **Probiotics** have also been studied for their role in reducing **enterohepatic bilirubin recycling**, but **their effect on hyperbilirubinemia remains inconclusive**¹².

Given these challenges, **Ursodeoxycholic Acid (UDCA)** has emerged as a promising **adjuvant therapy** for neonatal UH. UDCA is a **hydrophilic bile acid** widely used in treating **cholestatic liver diseases and primary biliary cholangitis**¹³. It is hypothesized to **enhance bilirubin clearance** through multiple mechanisms. UDCA increases **hepatic bile acid transporters** such as **BSEP (bile salt export pump) and MRP2 (multidrug resistance-associated protein 2)**, thereby promoting **biliary excretion of bilirubin**¹⁴. Additionally, UDCA **reduces enterohepatic**

circulation by binding to bile acids, preventing bilirubin reabsorption in the gut¹⁵. It also has anti-inflammatory and antioxidant properties, protecting hepatocytes from oxidative damage due to bilirubin overload¹⁶.

Animal studies have provided strong mechanistic evidence supporting the use of UDCA in neonatal hyperbilirubinemia. A study by **Cuperus et al. (2009)** in **Gunn rats**, a model for **Crigler-Najjar syndrome**, demonstrated that UDCA **accelerated bilirubin metabolism** and enhanced **fecal bilirubin excretion**¹⁷. Similarly, **Mendez et al. (1998)** observed that UDCA facilitated **enterohepatic cycling of bilirubin** in rodents, suggesting a potential **increase in bilirubin turnover**⁸. However, despite promising **preclinical data**, human clinical evidence remains **limited and inconclusive**.

Several clinical studies have investigated the efficacy of UDCA in neonatal jaundice. A randomized controlled trial (RCT) by Bhardwaj et al. (2020) on 100 term neonates (TSB levels of 13-20 mg/dL) found that neonates receiving UDCA with PT had a significantly faster bilirubin decline than those on PT alone (TSB at 24 hours of PT: 11.78 mg/dL vs. 12.47 mg/dL, respectively)¹⁹. Another study by Honar et al. (2016) demonstrated that UDCA administration shortened phototherapy duration by 24 hours, suggesting its effectiveness as an adjuvant the9rapy²⁰. Similarly, Hasan et al. (2015) reported a significant reduction in TSB levels and phototherapy duration with no adverse effects, further supporting UDCA's potential role in neonatal hyperbilirubinemia management²¹. But some studies like Maduka Donatus et al.(2019) have found no significant advantage of UDCA+PT over phototherapy alone³¹. Further research to establish optimal dosing, timing, and long-term safety, are required before UDCA can be advocated as adjuvant to PT.

Given the **limitations and side effects of phototherapy**, the potential **adverse effects of prolonged bilirubin exposure**, and the **economic burden of prolonged hospital stays**, an **effective**, **safe**, **and accessible adjuvant therapy is needed**. UDCA, with its **bile acidmodulating properties**, offers a **potentially cost-effective and non-invasive** approach to enhancing bilirubin clearance. However, due to the **lack of large-scale trials or review articles ,and some conflicting results**, further studies are essential to evaluate its efficacy and safety in neonates with **unconjugated hyperbilirubinemia**(UCHB)

Our present study aims to assess the role of UDCA in term neonates with UCHB receiving PT and determine whether UDCA reduces phototherapy duration, lowers peak bilirubin levels rapidly and more effectively, and decreases hospitalization duration. This study becomes particularly significant in resource-limited settings, where access to advanced phototherapy equipment and exchange transfusion facilities may be restricted. By providing scientific evidence on the effectiveness of UDCA, this study could contribute to developing improved guidelines for managing neonatal hyperbilirubinemia ,say starting UDCA along with PT and reducing the burden on healthcare systems.

AIM AND OBJECTIVES

AIM:

To assess the role of ursodeoxycholic acid (UDCA) as an adjuvant to phototherapy in reducing unconjugated hyperbilirubinemia.

OBJECTIVES

To evaluate the effect of ursodeoxycholic acid

1.Reducing unconjugated bilirubin levels

2.Duration of phototherapy of infants undergoing phototherapy for neonatal hyperbilirubinemia.

REVIEW OF LITERATURE

Neonatal jaundice is one of the most frequently encountered conditions in neonatology, affecting nearly 60% of term neonates and 80% of preterm neonates within the first week of life¹. is primarily caused by **unconjugated hyperbilirubinemia** due to immature liver function and increased breakdown of fetal erythrocytes.

While mild jaundice usually doesn't require any intervention, but severe cases pose a risk of neurotoxicity, such as kernicterus.**PT** is the standard treatment, but has its limitations like dehydration, retinal damage and oxidative stress.

Recent studies suggest that **UDCA**, a bile acid,could be an effective adjuvant therapy by enhancing bilirubin clearance,reducing duration of phototherapy and improving outcomes,though results are still inconclusive.

1. Physiology of Bilirubin Metabolism:

Bilirubin metabolism is a complex physiological process that involves the breakdown of red blood cells (RBCs), hepatic conjugation, and excretion via the biliary and renal systems. The life span of RBCs is approximately **120 days**, after which they undergo degradation in the **reticuloendothelial system (RES)** of the **liver and spleen**. During this process, hemoglobin (Hb) is broken down into its components: **iron, proto-porphyrins, and protein globin chains**. The iron is recycled for new hemoglobin synthesis, while the globin chains are broken down into acids for reuse. The proto-porphyrins undergo further degradation to form **bilirubin**, which is an insoluble pigment and requires transport to the liver for further processing.

Unconjugated bilirubin (UCB), which is **lipophilic and water-insoluble**, binds to **albumin** in the bloodstream to facilitate its transport to the liver.(4- 5mg bilirubin bind to 1 gm of Albumen) The liver plays a crucial role in bilirubin metabolism, where hepatocytes conjugate bilirubin glucuronic acid through with the enzyme UDPglucuronosyltransferase (UGT1A1). This transformation results in the formation of conjugated bilirubin, which is water-soluble and can be excreted efficiently. The conjugated bilirubin is subsequently transported via the **bile ducts** into the **small intestine**, where it undergoes further metabolism. Within the intestines, conjugated bilirubin is converted into urobilinogen by bacterial enzymes. Some of the urobilinogen is reabsorbed into the enterohepatic circulation, returning to the liver for re-excretion, while the majority is oxidized into **stercobilin**, which is excreted in feces and gives stool its characteristic **brown color**. A small fraction of urobilinogen is also absorbed into the systemic circulation, filtered by the kidneys, and excreted in urine as urobilinogen, contributing to the yellow pigmentation of urine.

Disruptions in bilirubin metabolism can lead to pathological conditions such as **hyperbilirubinemia, jaundice**. Liver diseases like **hepatitis,** impair bilirubin conjugation, leading to an accumulation of **unconjugated bilirubin** in the bloodstream, along with increased conjugated bilirubin(>20% of total bilirubin). Additionally, **biliary obstruction**, prevent the excretion of **conjugated bilirubin**, causing its build-up in the blood and subsequent excretion in urine. These pathological conditions result in **jaundice**, a condition

characterized by yellow discoloration of the skin and sclera due to elevated bilirubin levels, and orange yellow or dark yellow urine while voiding itself.

Any disturbance in these pathways can lead to **clinically significant hyperbilirubinemia**, necessitating timely medical intervention.

2. Pathophysiology of Neonatal Jaundice

Neonatal jaundice occurs due to an imbalance between **bilirubin production**, **hepatic conjugation**, **and excretion**. The primary pathological mechanisms involve **increased bilirubin production**, **decreased hepatic clearance**, **and increased enterohepatic recirculation**.

1. Increased Bilirubin Production

- Neonates have a higher RBCs turnover rate due to a shorter lifespan of fetal red blood cells (RBCs) ^{[1].}
- Increased hemolysis occurs in conditions such as ABO/Rh incompatibility, G6PD deficiency, and hereditary spherocytosis, leading to excessive unconjugated bilirubin (UCB) production ^{[2].}
- **Inefficient hepatic uptake**: The immaturity of hepatocyte membrane carriers leads to slower bilirubin transport into liver cells, further exacerbating hyperbilirubinemia ^{[3].}

2. Decreased Hepatic Clearance

• The neonatal liver has **reduced UGT1A1 activity**, the enzyme responsible for bilirubin conjugation ^{[4].}

- This results in **delayed conversion of lipophilic UCB to hydrophilic conjugated bilirubin**, prolonging bilirubin circulation in the bloodstream ^{[5].}
- **Premature infants** have even lower enzyme activity, significantly increasing their risk for jaundice ^{[6].}

3. Increased Enterohepatic Circulation

- The neonatal intestine has **low levels of gut microbiota**, reducing the conversion of conjugated bilirubin to stercobilin and urobilin ^{[7].}
- β-glucuronidase activity in the neonatal gut deconjugates bilirubin, allowing it to be reabsorbed into the bloodstream, thereby prolonging jaundice ^{[8].}
- Breastfeeding-associated jaundice is attributed to enhanced enterohepatic recirculation, often seen in breastfeeding infants with inadequate milk intake, leading to a delay in bilirubin elimination ^{[9].}




Fig.2: Pathophysiology of bilirubin metabolism (Tsai MT et al .2018)⁴¹

Complications of Severe Hyperbilirubinemia

If left untreated, **excessive bilirubin crosses the blood-brain barrier**, leading to **bilirubin encephalopathy** (**kernicterus**), a life-threatening neurological condition.

- 1. Early Signs (Acute Phase)
- 2. Lethargy, poor feeding, and hypotonia (low muscle tone)^{[10].}
- 3. High-pitched cry and irritability ^{[11].}
- 4. **Opisthotonus** (abnormal posturing with arching of the back)^{[12].}

2. Advanced Neurological Symptoms

- Seizures, apnea, and fever ^{[13].}
- Hearing impairment and developmental delay ^[14].
- Cerebral palsy and long-term cognitive deficits ^{[15].}


Long-Term Consequences of Untreated Severe Jaundice

- Choreoathetoid cerebral palsy: A movement disorder caused by bilirubininduced neuronal damage(BIND) ^{[16].}
- Hearing impairment and speech deficits ^{[2].}
- Gaze abnormalities due to oculomotor dysfunction ^{[12].}
- Cognitive and learning disabilities, impacting school performance ^{[4].}

Early detection and appropriate management are crucial to prevent bilirubin toxicity and long-term neurological damage. While **phototherapy** remains the standard treatment, recent research has focused on **adjuvant therapies** such as **UDCA**, which may enhance bilirubin clearance and minimize complications¹⁶.

Future studies should aim at establishing evidence-based guidelines for the **safe and effective use of UDCA**, and other adjuvants in neonatal jaundice management.

Unconjugated Neonatal Hyperbilirubinemia: Complications



Authors:

Parthiv Amin

^{15.} Fig.3: Complications of Unconjugated Neonatal Hyperbilirubinemia and Bilirubin-Induced Neurologic Dysfunction (BIND) (Amin P. 18) ⁴²

3. Standard Treatment of Neonatal Hyperbilirubinemia

Neonatal hyperbilirubinemia requires prompt and effective management to prevent **bilirubin toxicity** and long-term **neurological complications** such as **kernicterus**. The **primary goal** of treatment is to **reduce serum bilirubin to safe levels** and prevent its accumulation in the **central nervous system** (**CNS**). The two therapeutic approaches include **phototherapy** (**PT**) and **exchange transfusion**, both of which have been extensively studied and utilized in clinical settings.

3.1 Phototherapy

Phototherapy (PT) is the **first-line treatment** for neonatal hyperbilirubinemia. It **facilitates the conversion** of **unconjugated bilirubin (UCB)** into **water-soluble photo-isomers**, which are **easily excreted via urine and bile** without requiring hepatic conjugation ^{[1].}

Mechanism of Action

Phototherapy exerts its effect through three primary pathways ^{[2]:}

- **Photo-oxidation:** Exposure to high-intensity blue light (wavelength 460–490 nm) oxidizes bilirubin to more **polar compounds**, facilitating excretion.
- **Structural Isomerization:** UCB is converted to **lumirubin**, a water-soluble form that bypasses hepatic metabolism and is rapidly excreted.
- **Configurational Isomerization:** Changes in the molecular configuration of bilirubin increase its solubility and allow direct elimination.

Types of Phototherapy

- 1. **Conventional Phototherapy:** Uses **fluorescent**, **CFL or LED lights(SS/DS)** to provide continuous exposure.
- 2. **Intensive Phototherapy:** High-intensity **blue LED light** exposure, which accelerates bilirubin degradation.
- ^{3.} Fiber-Optic Phototherapy (Bili Blanket): Uses fiber-optic cables placed in contact with the neonate's skin, reducing the risk of thermal stress and dehydration ^{[3].}

Clinical Efficacy

Studies have shown that **intensive phototherapy** significantly reduces **total serum bilirubin (TSB) levels**(3-4 mg/dl)in 24 hours, with a faster decline in **preterm neonates** ^{[4].} The **American Academy of Pediatrics (AAP) guidelines** recommend **early initiation of phototherapy** based on bilirubin levels relative to postnatal age and risk factors ^{[1].}

Adverse Effects of Phototherapy

Despite its efficacy, phototherapy is associated with potential complications ^[5]:

- Bronze Baby Syndrome: Occurs due to bilirubin photoproducts accumulating in the skin, resulting in grayish-brown skin discoloration, particularly in neonates with cholestasis.
- Dehydration and Electrolyte Imbalance: Increased insensible water loss necessitates adequate hydration during treatment.

- **Retinal Damage and Oxidative Stress:** Prolonged exposure to high-intensity light may induce **oxidative injury** to **retinal cells**, requiring **eye protection** ^{[6].}
- Interruption of Mother-Infant Bonding: Continuous phototherapy often requires separation from the mother, affecting early breastfeeding initiation and bonding.

Strategies to Enhance Phototherapy Efficiency

- Maximizing Surface Area Exposure: Positioning the neonate to ensure maximum skin exposure to the light source.
- ^{2.} Higher Spectral Intensity: Using LED-based phototherapy units that provide narrow-band blue light in the 460–490 nm range ^{[7].}
- ^{3.} Adjunctive Pharmacotherapy: Recent studies have explored the use of ursodeoxycholic acid (UDCA) as a synergistic agent to phototherapy, promoting faster bilirubin clearance ^{[8].}
- 3.2 Exchange Transfusion

Exchange transfusion (ET) is a **second-line therapy**, reserved for neonates with **severe hyperbilirubinemia** who fail to respond to **intensive phototherapy** or are at risk of developing **acute bilirubin encephalopathy** ^{[9].}

Indications for Exchange Transfusion

According to AAP guidelines, ET is indicated in neonates with ^{[1]:}

• TSB levels exceeding exchange threshold values relative to age and risk factors.

- Failure of phototherapy to reduce bilirubin levels effectively.
- Signs of acute bilirubin toxicity (lethargy, hypotonia, poor feeding, seizures).

Procedure and Mechanism

- ET involves the **removal of bilirubin-laden blood** and its **replacement with donor blood**, effectively reducing TSB and preventing **CNS deposition** of bilirubin ^{[4].}
- Typically performed via **umbilical vein catheterization**, where **small aliquots of blood** (5–10 mL/kg) are exchanged to prevent **hemodynamic instability**.

Risks and Complications of Exchange Transfusion

While effective, ET is associated with higher risks compared to ^{[10]:}

- Infections and Sepsis: Increased risk of nosocomial infections due to repeated catheterization.
- Thrombocytopenia: Loss of platelets during transfusion, necessitating platelet support.
- **Hypocalcemia and Metabolic Derangements:** Citrate in transfused blood **binds calcium**, leading to **hypocalcemia**, which may cause **cardiac arrhythmias**.
- Hemodynamic Instability: Large-volume blood exchange can cause fluctuations in blood pressure and anemia.

Current Trends and Advancements in Exchange Transfusion

- 1. Minimizing ET through Early Phototherapy: Studies suggest that aggressive phototherapy initiation reduces the need for ET ^{[3].}
- 2. **Partial Exchange Transfusion:** Used in preterm neonates to **gradually** lower bilirubin levels without significant hemodynamic compromise.
- 3. Adjunctive Therapy with Antioxidants: Research suggests that N-acetylcysteine and UDCA may help reduce bilirubin-induced oxidative stress, thus lowering the need for ET ^{[7].}

4. Role of UDCA in Neonatal Jaundice

Neonatal jaundice is a prevalent condition, primarily caused by **unconjugated hyperbilirubinemia** (**UCB**), which can lead to **bilirubin neurotoxicity and kernicterus** if not effectively managed. While **phototherapy** (**PT**) remains the primary treatment, certain limitations, such as **prolonged hospital stays**, **dehydration**, **and feeding difficulties**, have led to research on **adjunctive pharmacological therapies** to enhance bilirubin clearance. **Ursodeoxycholic acid (UDCA)**, a **hydrophilic bile acid**, has emerged as a promising therapeutic agent due to its **choleretic**, **hepatoprotective**, **and anti-inflammatory properties**^{[1].} This section delves into the **mechanism of action**, **clinical evidence**, **and safety profile** of UDCA in the management of **neonatal jaundice**.

4.1 Mechanism of Action of UDCA

UDCA is a **secondary bile acid** that plays a crucial role in **hepatic bile acid metabolism and bilirubin clearance**. It is extensively used in the treatment of **neonatal cholestasis** and **liver dysfunctions** due to its ability to **stimulate bile flow and reduce hepatocellular damage**. Its potential in **neonatal jaundice** arises from its ability to **enhance bilirubin elimination via multiple pathways**^{[1].}

Key Mechanisms by Which UDCA Enhances Bilirubin Clearance:

- 1. Induction of Hepatic Bile Acid Transporters:
 - UDCA upregulates bile salt export pumps (BSEP) and multidrug resistance proteins (MRP2) in hepatocytes, facilitating enhanced biliary excretion of conjugated bilirubin ^{[2].}
- 2. Reduction of Enterohepatic Circulation of Bilirubin:
 - By promoting intestinal bile acid secretion, UDCA decreases the reabsorption of bilirubin in the enterohepatic circulation, leading to accelerated fecal bilirubin disposal ^{[3].}
- 3. Membrane-Stabilizing and Anti-Oxidative Effects:
 - UDCA replaces toxic hydrophobic bile acids, thus reducing oxidative stress and hepatocellular apoptosis, leading to enhanced hepatic protection ^{[4].}
- 4. Enhancement of Hepatic Bilirubin Uptake and Conjugation:
 - UDCA stimulates the expression of cytochrome P450 enzymes and UGT1A1, which are key enzymes involved in bilirubin conjugation and metabolism, leading to efficient bilirubin detoxification and clearance
 [5].

These mechanisms collectively contribute to **enhanced bilirubin elimination**, positioning UDCA as a **potential adjunctive therapy to phototherapy in neonates with unconjugated hyperbilirubinemia**.

4.2 Clinical Evidence Supporting UDCA Use in Neonatal Jaundice

Several **randomized controlled trials (RCTs) and animal model studies** have assessed the efficacy of UDCA in **reducing neonatal hyperbilirubinemia**. The following studies provide **substantial clinical evidence** for its role as an **adjuvant to phototherapy**:

- Bhardwaj et al. (2020) [6] conducted an RCT on 100 term neonates with total serum bilirubin (TSB) levels between 13–20 mg/dL and found that UDCA significantly reduced TSB within 24 hours when administered alongside phototherapy.
 - At 24 hours, mean bilirubin levels in the UDCA + PT group were 11.78 mg/dL, compared to 12.47 mg/dL in the phototherapy-only group, demonstrating a faster decline in bilirubin levels.
- 2. Hassan et al. (2015) [7] demonstrated that UDCA reduced phototherapy duration by an average of 24 hours, thereby shortening hospital stays and lowering healthcare costs. This reduction in phototherapy exposure also minimized phototherapy-associated complications such as dehydration, electrolyte imbalances, and interruption of breastfeeding.
- 3. Honar et al. (2016) [1] suggested that UDCA enhances fecal bilirubin excretion, reinforcing its role in reducing enterohepatic bilirubin circulation, which accelerates UCB elimination and decreases serum bilirubin levels.

- Cuperus et al. (2009) [4] performed an animal study in Gunn rats, a wellestablished model for neonatal jaundice, and confirmed that UDCA accelerates UCB clearance by increasing hepatic and fecal bilirubin elimination.
- 5. Mendez et al. (1998) [8] investigated dietary UDCA supplementation in rodents and found that it enhanced enterohepatic bilirubin turnover, further supporting its potential role as an adjunctive therapy for neonatal jaundice.

These studies collectively provide **strong evidence** that **UDCA**, **when used in conjunction with phototherapy, enhances bilirubin clearance, shortens phototherapy duration, and improves clinical outcomes in neonates with hyperbilirubinemia**.

4.3 Safety Profile of UDCA in Neonates

UDCA has been extensively studied in **neonatal and pediatric populations**, particularly in the treatment of **cholestatic liver diseases**. Its **safety profile in neonates undergoing phototherapy for unconjugated hyperbilirubinemia** has been evaluated, revealing a **favorable risk-benefit ratio**.

Key Safety Aspects of UDCA Administration in Neonates:

- 1. Well-Tolerated at Recommended Doses:
 - Neonates receiving 10–15 mg/kg/day of UDCA exhibit no significant adverse effects, demonstrating its high safety margin (Beuers et al., 2015)
 [2].
- 2. Minimal Gastrointestinal Disturbances:

- A few neonates experience mild diarrhea and transient stool color changes, but no clinically significant hepatic or systemic toxicity has been reported (Hassan et al., 2015) [7].
- 3. No Evidence of Hepatic Dysfunction:
 - Studies indicate that UDCA does not **induce hepatic enzyme abnormalities** or **cause cholestasis** in neonates (Kaplan et al., 2014) [3].
- 4. No Long-Term Neurodevelopmental Impairments:
 - Follow-up studies suggest that **UDCA exposure in neonates does not** result in adverse neurodevelopmental outcomes (Honar et al., 2016) [1].

These findings highlight the **safety and tolerability** of UDCA as a **potential pharmacological adjunct** in **neonatal jaundice management**. However, further **large-scale RCTs** are warranted to determine **long-term safety and establish standardized dosing guidelines**.

5. Comparative Analysis of UDCA vs. Other Adjuvant Therapies

Neonatal jaundice, primarily caused by **unconjugated hyperbilirubinemia** (UCB), necessitates effective treatment strategies to prevent **bilirubin neurotoxicity and kernicterus**. While **PT** remains the standard treatment, various **pharmacological adjuncts** have been explored to **enhance bilirubin clearance and reduce phototherapy duration**. Among these, **Ursodeoxycholic Acid** (UDCA) has demonstrated **promising efficacy and safety**; however, other agents such as **phenobarbital**, **clofibrate** have also been investigated for their potential therapeutic benefits. This section provides a comparative analysis of UDCA with other adjuvant therapies, highlighting their mechanisms, efficacy, and safety concerns, as studied by different researchers.

5.1 Phenobarbital

Phenobarbital is a **barbiturate** that **induces hepatic enzyme activity**, particularly **UDPglucuronosyltransferase (UGT1A1)**, which plays a crucial role in **bilirubin conjugation**. It has been studied as an adjunct therapy in neonatal hyperbilirubinemia due to its ability to **increase bilirubin conjugation and excretion** (Maisels et al., 2019) [1].

Advantages of Phenobarbital in Neonatal Jaundice:

- Enhances hepatic UGT1A1 expression, leading to increased bilirubin conjugation and subsequent excretion.
- **Reduces serum bilirubin levels** in neonates with **hemolytic disease** (e.g., Rh incompatibility, G6PD deficiency) (Bhutani et al., 2013) [2].

Limitations and Adverse Effects:

- **Requires prolonged administration** (several days to weeks) to achieve a significant effect, making it **less practical for acute bilirubin reduction** (Hansen, 2011) [3].
- Sedative effects can lead to respiratory depression and feeding difficulties, which are undesirable in neonates (Kaplan et al., 2014) [4].

Comparison with UDCA:

• UDCA has a **faster onset of action**, whereas **phenobarbital requires prolonged administration** for a clinically significant effect.

5.2 Clofibrate

Clofibrate, a **peroxisome proliferator-activated receptor-alpha** (**PPAR-***α*) **agonist**, has been studied for its **potential role in bilirubin metabolism**. It **stimulates hepatic bilirubin conjugation and excretion** by increasing **hepatic UGT1A1 activity** (Beuers et al., 2015) [5].

Efficacy and Advantages of Clofibrate:

- **Reduces serum bilirubin levels** by **stimulating bilirubin glucuronidation**, similar to **phenobarbital** but with a **quicker onset of action**.
- Shortens phototherapy duration in neonates with non-hemolytic hyperbilirubinemia (Hassan et al., 2015) [6].

Limitations and Adverse Effects:

- Studies on clofibrate have shown inconsistent results, with variable efficacy across different populations (Honar et al., 2016) [7].
- Potential for adverse effects on lipid metabolism, including alterations in serum triglyceride and cholesterol levels, which may pose long-term metabolic risks (Cuperus et al., 2009) [8].

Comparison with UDCA:

• UDCA has a well-established safety profile, whereas clofibrate's long-term metabolic effects remain a concern.

6. Limitations and Need for Further Research

Despite **promising clinical findings**, the use of **UDCA in neonatal jaundice** is still **not universally standardized**. The **current limitations** include:

- Limited large-scale RCTs: Most studies assessing UDCA have been small-scale or animal-based, necessitating larger, multicenter trials to establish definitive clinical guidelines (Honar et al., 2016) [7].
- Long-term safety concerns: While UDCA has demonstrated short-term efficacy, long-term neurodevelopmental and metabolic outcomes remain uncertain.
 Future studies should assess long term cognitive, hepatic, and metabolic effects in infants treated with UDCA (Beuers et al., 2015) [5].
- Optimal dosing regimens: The exact dosing regimen for UDCA in neonatal jaundice has not been standardized, and further research is needed to determine the most effective and safe dose range (Hansen, 2011) [3].

Future research should focus on:

- 1. Randomized controlled trials (RCTs) with larger sample sizes to validate UDCA's efficacy.
- 2. Longitudinal studies assessing long-term neurodevelopmental outcomes.

3. Comparative studies analyzing UDCA's efficacy against, and in combinations with other pharmacological adjuncts, particularly phenobarbital and clofibrate.

Compared to other adjuvant therapies:

- UDCA has a more rapid onset of action than phenobarbital and does not require prolonged administration.
- Unlike clofibrate, UDCA does not pose metabolic risks, making it a safer alternative.

While **initial studies indicate a favorable safety profile**, **further large-scale clinical trials** are necessary to **validate its routine use in neonatal care**.

Future research should focus on

- 1. Establishing standardized dosing regimens and assessing long-term outcomes to ensure that UDCA becomes an integral part of neonatal jaundice management.
- 2. Combination of more than one adjuvants , Phenobarb /clofibrate/ UDCA for better and faster reduction of unconjugated bilirubin in neonates , and to reduce the side-effects/ toxicity of the adjuvants.

NEED FOR STUDY:

Our present study aims to assess the role of **UDCA** in term neonates with **UCHB** receiving **PT** and determine whether **UDCA** reduces phototherapy duration, lowers peak bilirubin levels rapidly and more effectively, and decreases hospitalization duration. This study becomes particularly significant in resource-limited settings, where access to advanced phototherapy equipment and exchange transfusion facilities may be restricted. By providing scientific evidence on the effectiveness of **UDCA**, this study could contribute to developing improved guidelines for managing **neonatal hyperbilirubinemia**, say starting **UDCA along with PT** and reducing the burden on healthcare systems.

MATERIALS AND METHODS

Study Design

This is a **prospective**, **interventional**, **randomized controlled trial** (**RCT** conducted at the **Neonatal Intensive Care Unit** (**NICU**) of Shri B.M. Patil Medical College, Hospital and **Research Centre**, **Vijayapura**, **Karnataka**. The study aims to assess the efficacy of **Ursodeoxycholic Acid** (**UDCA**) as an adjunct to phototherapy in the management of **unconjugated hyperbilirubinemia in term neonates**.

Study Population

The study includes **full-term neonates** (>37 weeks of gestation) diagnosed with unconjugated hyperbilirubinemia requiring phototherapy. Eligible neonates are recruited after obtaining written informed consent from parents or guardians.

Inclusion Criteria

- Full-term neonates (>37 weeks of gestation).
- Total serum bilirubin (TSB) >13 mg/dL, requiring phototherapy as per AAP guidelines.
- Birth weight >2 kg.
- Clinically stable neonates without congenital malformations.

Exclusion Criteria

- Neonates with congenital anomalies.
- Neonates with systemic sepsis, metabolic disorders, or hemolytic disease (e.g., G6PD deficiency, Rh/ABO incompatibility).

• Neonates with direct hyperbilirubinemia (conjugated bilirubin >20% of TSB).

Sample Size Calculation

A total of **100 neonates** (50 in the **UDCA group** and 50 in the **control group**) are included. The sample size was determined using **G*Power 3.1.9.4 software**, based on previous studies that showed a **statistically significant reduction in bilirubin levels** in neonates receiving **UDCA plus phototherapy** compared to **phototherapy alone**.

Randomization and Study Groups

- Group 1 (UDCA + Phototherapy Group): Neonates receive oral UDCA (10–15 mg/kg/day) in divided doses along with standard phototherapy.
- Group 2 (Phototherapy-Only Control Group): Neonates receive standard phototherapy alone without UDCA administration.
- Randomization is performed using **computer-generated random allocation**.

Intervention and Treatment Protocol

- UDCA Administration: Administered orally or via a nasogastric tube mixed with 1–2 mL of breast milk or sterile water.
- Phototherapy Protocol:
 - Neonates are placed under LED phototherapy as per AAP guidelines.
 - TSB is monitored every 12 hours until it drops below 10 mg/dL.
 - Exchange transfusion is considered if bilirubin levels exceed critical thresholds.

Data Collection

Data is collected **prospectively** using a structured proforma. Parameters assessed include:

- Demographic data: Birth weight, gestational age, Apgar scores.
- **Bilirubin levels:** Baseline TSB and serial bilirubin measurements every **12 hours** until phototherapy discontinuation.
- Duration of phototherapy (in hours/days).
- Neonatal hydration status (weight loss percentage, urine output, and serum electrolytes).
- Any adverse effects of UDCA (diarrhea, feeding intolerance, vomiting).

Outcome Measures

The primary outcome is **the rate of bilirubin decline** (**mg/dL/hr**) **and total duration of phototherapy**. The secondary outcomes include:

- Hospital stay duration (in days).
- Adverse effects of UDCA.
- Requirement for exchange transfusion.

Statistical Analysis

Data is analyzed using **SPSS software (Version 20)**. Continuous variables are expressed as **mean ± standard deviation (SD)** and compared using the **independent sample t-test** (for normally distributed variables) or **Mann-Whitney U test** (for non-normally distributed variables).

Categorical variables are analyzed using the **Chi-square test/Fisher's exact test**. A **p-value <0.05** is considered statistically significant.

Ethical Considerations

The study has been **approved by the Institutional Ethics Committee of Shri B.M. Patil Medical College**. Written **informed consent** is obtained from parents before enrollment. The study adheres to the **Declaration of Helsinki guidelines** for human research.

This study evaluates the **potential role of UDCA as an adjunct therapy** in neonatal jaundice management. If proven effective, UDCA could **reduce the duration of phototherapy, hospital stay, and healthcare burden**, improving overall neonatal outcomes.


OBSERVATIONS AND RESULTS

Table 1: Baseline Characteristics of the Study Population


This table presents the demographic and clinical characteristics of the enrolled neonates in both groups.

Parameter	UDCA + Phototherapy Group (n=50) (CASE)	Phototherapy-Only Group (n=50) (CONTROL)	p-value
Gestational Age (weeks)	38.4 ± 1.2	38.2 ± 1.3	0.412
Birth Weight (kg)	2.79 ± 0.43	2.76 ± 0.4	0.528
Mode of Delivery (NVD/LSCS/Elective LSCS)	11/36/03	08/42/00	0.763
APGAR Score at Birth	8 ± 0.0	8 ± 00	0.621
APGAR Score at 5 min	9 ± 0.0	9 ± 0.0	0.654
Neonatal Gender (M/F)	24/26	31/19	0.734
Maternal Blood Group A/B/O/ AB	17/13/18/02	18/17/13/02	0.834


No significant differences in **gestational age, birth weight, APGAR scores, gender distribution, or maternal blood group** were observed between the two groups (p > 0.05). The comparable baseline characteristics ensure **homogeneity of the study population**, strengthening the reliability of outcome analysis.



Graph.1 A bar graph representation of baseline characterstics



Graph.2 A line graph representation mode of delivery distribution




Graph.3 A bar graph representation of neonatal gender distribution

Table 2: Clinical Parameters at Admission

This table outlines the clinical status of neonates at the time of NICU admission.

Parameter	UDCA + Phototherapy Group (n=50) (CASE)	Phototherapy-Only Group (n=50) (CONTROL)	p-value			
Heart Rate (bpm)	142 ± 9	143 ± 8	0.621			
Respiratory Rate (breaths/min)	51 ± 6	50 ± 5	0.543			
Capillary Filling Time (sec)	2.3 ± 0.4	2.4 ± 0.5	0.698			
SpO ₂ Right Upper Limb (%)	98.5 ± 1.2	98.3 ± 1.4	0.814			
SpO ₂ Left Lower Limb (%)	97.8 ± 1.3	97.6 ± 1.5	0.792			

Both groups demonstrated **comparable vital signs**, suggesting **similar physiological status** at admission. The **absence of significant differences** (p > 0.05) indicates that UDCA did not introduce immediate physiological alterations.




Graph.4 A line graph representation of clinical parameters at admission

Table 3: Serial Bilirubin Measurements

This table compares the **mean total serum bilirubin (TSB) and unconjugated bilirubin (UCB) levels** over different time points between the two groups.

Time Point	UDCA + Phototherapy Group (n=50) (CASE)	Phototherapy-Only Group (n=50) (CONTROL)	p-value		
TSB at Admission	18.2 ± 3.12	18.42 ± 2.4	0.693		
TSB at 24 Hours	13.1± 2.25	13.9 ± 2.19	0.07		
TSB at 48 Hours	9 .3± 1.75	9.8 ± 1.9	0.175		
UCB at Admission	17.83 ± 2.92	18.12 ± 0.4	0.488		
UCB at 24 Hours	12.9 ± 2.0	13.6 ± 2.12	0.092		
UCB at 48 Hours	9.08 ± 1.7	9.73 ± 1.9	0.074		




Graph.5 A bar graph representation of mean total serum bilirubin (TSB) and unconjugated bilirubin (UCB) levels

Table 4: Impact on Phototherapy and NICU Stay

This table evaluates the effect of **UDCA on phototherapy duration and NICU hospitalization**.

Parameter	UDCA + Phototherapy Group	p-value	
Duration of Phototherapy (hours)	47.84 ± 2.5	48.22 ± 5.5	0.66
NICU Stay (days)	3.02 ± 0.24	3.0 ± 0.2	0.651

The **p-values suggest no statistically significant** (p >0.05).




Graph.6 A bar graph representation of the impact on Phototherapy and NICU Stay

Table 5: Safety and Adverse Effects of UDCA

This table evaluates the **tolerability and safety profile** of UDCA.

Adverse Effect	UDCA + Phototherapy Group (n=50)	Phototherapy-Only Group (n=50)	p-value				
Diarrhea	0	0	0.00				
Vomiting	3	0	0.242				
Abdominal Distension	0	0	0.00				

The **p-values suggest no statistically significant** difference in side effects (p> 0.05).



Graph.7 A column bar graph representation of Safety and Adverse Effects of UDCA

DISCUSSION

Neonatal hyperbilirubinemia is one of the most commonly encountered conditions in neonatology, affecting nearly 60-80% of term neonates and up to 90% of preterm neonates within the first week of life. The immature hepatic conjugation process and increased enterohepatic circulation of bilirubin contribute to this transient condition. While most cases are self-limiting, severe hyperbilirubinemia can lead to bilirubin-induced neurological dysfunction (BIND), acute bilirubin encephalopathy (ABE), and kernicterus, which can cause irreversible neurological impairment. Early and effective treatment is, therefore, crucial in preventing long-term complications associated with neonatal jaundice.

Phototherapy (PT) is the first-line treatment for neonatal hyperbilirubinemia and works by converting unconjugated bilirubin (UCB) into water-soluble photo-isomers, which are readily excreted without hepatic conjugation. Despite its effectiveness, prolonged phototherapy is associated with adverse effects such as dehydration, electrolyte imbalance, oxidative stress, and disruption of maternal-infant bonding. Moreover, in severe cases, exchange transfusion remains the last resort, which carries its own risks, including hemodynamic instability, thrombocytopenia, and infections. Given these limitations, adjuvant pharmacotherapy has gained interest in recent years.

Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, is widely used in the treatment of cholestatic liver diseases due to its ability to enhance bile flow, reduce enterohepatic circulation, and protect hepatocytes from oxidative stress. Several studies have explored UDCA as a potential adjunct to phototherapy in neonatal jaundice, hypothesizing that it enhances bilirubin clearance by upregulating bile acid transporters and reducing intestinal bilirubin reabsorption. However, existing clinical studies present conflicting results, with some showing significant reductions in phototherapy duration and others reporting no additional benefits over phototherapy alone.

The present study aimed to evaluate the efficacy of UDCA as an adjunct therapy to phototherapy in term neonates with unconjugated hyperbilirubinemia. The study assessed serial bilirubin levels, phototherapy duration, hospital stay, and adverse effects in neonates receiving UDCA + phototherapy versus those receiving phototherapy alone. Our findings were then compared with

existing literature to determine whether UDCA offers a significant advantage in neonatal hyperbilirubinemia management.

Baseline Characteristics of the Study Population

The study population included two groups—UDCA + phototherapy (PT) group and PT-only control group. Both groups were comparable in terms of gestational age, birth weight, mode of delivery, gender distribution, and maternal blood group, with no statistically significant differences (p > 0.05). The mean gestational age in the UDCA + PT group was 38.4 ± 1.2 weeks, while in the PT-only group, it was 38.2 ± 1.3 weeks. Similarly, the mean birth weight was 2.79 ± 0.43 kg in the UDCA group and 2.76 ± 0.4 kg in the PT-only group.

These findings are consistent with a study conducted by Honar et al. (2016), which also reported no significant differences (p > 0.05) in baseline neonatal characteristics when comparing neonates receiving UDCA versus phototherapy alone. A randomized controlled trial (RCT) by Bhardwaj et al. (2020) similarly found no pre-treatment differences in birth weight, gestational age, and gender distribution between the two groups, reinforcing the reliability of our outcome analysis.

Clinical Parameters at Admission

Both groups exhibited similar vital signs at the time of NICU admission. The mean heart rate was 142 ± 9 bpm in the UDCA + PT group versus 143 ± 8 bpm in the PT-only group (p = 0.621). The mean respiratory rate was 51 ± 6 breaths/min vs. 50 ± 5 breaths/min (p = 0.543). Other physiological parameters, such as capillary refill time and oxygen saturation levels, also showed no significant differences.

A study by Hasan et al. (2015) reported similar findings, concluding that UDCA administration did not cause immediate physiological alterations in neonates. These results suggest that UDCA does not have a significant impact on early clinical stabilization and that its primary effect is likely limited to enhancing bilirubin clearance rather than altering systemic hemodynamics.

Serial Bilirubin Measurements

A key aspect of our study was evaluating the rate of bilirubin decline over time. The mean total serum bilirubin (TSB) at admission was $18.2 \pm 3.12 \text{ mg/dL}$ in the UDCA + PT group versus $18.42 \pm 2.4 \text{ mg/dL}$ in the PT-only group (p = 0.693). Over 48 hours, TSB decreased to $9.3 \pm 1.75 \text{ mg/dL}$ in the UDCA group and $9.8 \pm 1.9 \text{ mg/dL}$ in the control group (p = 0.175).

In comparison, Bhardwaj et al. (2020) found that neonates receiving UDCA + PT had a significantly greater reduction in bilirubin levels at 24 hours (11.78 mg/dL vs. 12.47 mg/dL, p < 0.05). Similarly, Honar et al. (2016) reported a 24-hour bilirubin decline of 3.9 mg/dL in the UDCA group versus 3.1 mg/dL in the PT-only group (p = 0.048), suggesting a statistically significant advantage with UDCA. However, Hasan et al. (2015) observed that by 48 hours, mean bilirubin levels were 9.0 \pm 1.5 mg/dL in the UDCA group and 10.1 \pm 1.7 mg/dL in the control group (p = 0.03). Our findings were in alignment with these studies, showing a trend toward faster bilirubin clearance in the UDCA group, though not statistically significant.

Duration of Phototherapy and NICU Stay

In our study, the mean duration of phototherapy was 47.84 ± 2.5 hours in the UDCA + PT group compared to 48.22 ± 5.5 hours in the PT-only group (p = 0.66). Similarly, the mean NICU stay was 3.02 ± 0.24 days vs. 3.0 ± 0.2 days (p = 0.651).

Honar et al. (2016) found that UDCA reduced phototherapy duration by 24 hours in their study, a more pronounced effect than observed in our results. Similarly, Hasan et al. (2015) reported that hospital stay was significantly shorter in the UDCA group (2.8 ± 0.5 days vs. 3.4 ± 0.6 days, p < 0.05), suggesting that UDCA may improve recovery time.

Safety and Adverse Effects

Our study found no major adverse effects associated with UDCA use. Only 3 neonates in the UDCA group **experienced mild vomiting**, but no cases of diarrhea, abdominal distension, or metabolic derangements were reported.

Bhardwaj et al. (2020) reported transient diarrhea in 4% of neonates receiving UDCA, but no severe side effects. Similarly, Mohammed et al. (2020) found that UDCA was well tolerated in >95% of cases, reinforcing its favorable safety profile in neonates, our study has no reported diarrhea among neonates receiving UDCA and frequency, consistency in stools is similar in both groups.

Our study demonstrated that UDCA modestly accelerates bilirubin reduction and may shorten phototherapy duration, though the differences were not statistically significant. However, UDCA remained safe and well tolerated, with minimal side effects. While existing studies suggest a potential benefit of UDCA, larger multicenter RCTs are necessary to establish definitive recommendations for its routine use in neonatal jaundice management. The dose of UDCA in our study and the others also was 10/mg/kg/day/for 2days.Whether administration of a higher dose reduces the bilirubin levels fast is not known, can be studied further, with precaution that higher incidence and severity of side effect, likely with higher dosing.

Summary of the Study

- 1. Our study compared UDCA + PT vs. PT alone in 100 neonates, showing a modest bilirubin reduction in the UDCA group (TSB at 48 hours: $9.3 \pm 1.75 \text{ mg/dL}$ *V/S* $9.8 \pm 1.9 \text{ mg/dL}$, p = 0.175) in those NOT given UDCA, and no significant difference in phototherapy duration (47.84 ± 2.5 vs. 48.22 ± 5.5 hours, p = 0.66) or NICU stay (3.02 ± 0.24 vs. 3.0 ± 0.2 days, p = 0.651).
- UDCA was well tolerated, with only 3 cases of mild vomiting and no serious adverse effects. while UDCA may accelerate bilirubin clearance, the differences were not statistically significant.
- 3. Larger multicenter RCTs are needed to confirm its role in routine neonatal jaundice management.

LIMITATIONS:

- Small Sample Size: Limits generalizability; a larger cohort may yield more significant results.
- Single-Center Study: Findings may not apply to diverse healthcare settings.
- **Confounding Variables:** Uncontrolled factors (feeding patterns, genetic variations, maternal health) may have influenced outcomes.
- **Neonatal Haemoglobin Levels:** Variations not extensively analyzed, possibly affecting bilirubin production.

CONCLUSION

UDCA as adjuvant to PT has marginal benefit and minimal side effects, but the benefits are not statistically significant.

REFERENCES

- Maisel MJ. Neonatal jaundice. Pediatr Rev. 2006;27(12):443–53. DOI: 10.1542/pir.27-12-443.
- Hameed NN, Vilms R, Bhutani VK. Severe neonatal hyperbilirubinemia and adverse shortterm consequences in Baghdad, Iraq. Neonatology. 2011;100(1):57-63. DOI: 10.1159/000321987.
- Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015 Apr 1;62(1):S25-37. DOI: 10.1016/j.jhep.2015.02.023.
- Bhardwaj S, Gupta S, Jagrwal S, Meena M. Effect of Oral Ursodeoxycholic Acid on Indirect Hyperbilirubinemia in Neonates Treated With Phototherapy at a Tertiary Care Centre, Jaipur. Eur J Mol Clin Med. 2020;7(11).
- Hasan AM, Abdulrahman A, Husain RH. Effect of Ursodeoxycholic Acid in Lowering Neonatal Indirect Hyperbilirubinemia: A Randomized Controlled Trial. Merit Res J Med Med Sci. 2015;3(9):402-5.
- Honar N, Saadi EG, Saki F, Pishva N, Shakibazad N, Teshnizi SH. Effect of Ursodeoxycholic Acid on Indirect Hyperbilirubinemia in Neonates Treated With Phototherapy. J Pediatr Gastroenterol Nutr. 2016;62(1):97-100. DOI: 10.1097/MPG.000000000000929.
- Cuperus FJ, Hafkamp AM, Havinga R, Vitek L, Zelenka J, Tiribelli C, Ostrow JD, Verkade HJ. Effective treatment of unconjugated hyperbilirubinemia with oral bile salts in Gunn rats. Gastroenterology. 2009;136(2):673-82. DOI: 10.1053/j.gastro.2008.10.051.

- Mendez-Sanchez N, Brink MA, Paigen B, Carey MC. Ursodeoxycholic acid and cholesterol induce enterohepatic cycling of bilirubin in rodents. Gastroenterology. 1998;115(3):722-32. DOI: 10.1016/S0016-5085(98)70051-5.
- Hansen TW. The epidemiology of neonatal jaundice. Pediatr Med. 2021;4:18. DOI: 10.21037/pm-21-4.
- Kaplan M, Muraca M, Hammerman C, Rubaltelli FF, Vilei MT, Vreman HJ, Stevenson DK, et al. Imbalance between pro-oxidant and anti-oxidant mechanisms in newborns: the basis for pharmacologic strategies. Semin Perinatol. 2014;38(6):425-32. DOI: 10.1053/j.semperi.2014.08.007.
- Bhutani VK, Stark AR, Lazzeroni LC, Poland R, Gourley GR, Kazmierczak S, Meloy L, et al. Predischarge screening for severe neonatal hyperbilirubinemia identifies infants at risk for adverse outcomes. J Pediatr. 2013;162(3):477-82. DOI: 10.1016/j.jpeds.2012.08.022.
- Shapiro SM. Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND). J Perinatol. 2003;23(5):368-9. DOI: 10.1038/sj.jp.7210939.
- Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant ≥35 weeks' gestation: an update with clarifications. Pediatrics. 2019;124(4):1193-8. DOI: 10.1542/peds.2009-0329.
- 14. Hansen TW. Pathophysiology of neonatal jaundice. Clin Perinatol. 2011;38(3):643-59.DOI: 10.1016/j.clp.2011.00.002.

- 16. Beuers U, Bilir BM, Newton J, Fischer S, Trauner M. Molecular pathogenesis of bile acidinduced hepatocyte injury. J Hepatol. 2020;72(4):746-63. DOI: 10.1016/j.jhep.2019.12.022.
- Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage-mechanisms and management approaches. N Engl J Med. 2013;369(21):2021-30. DOI: 10.1056/NEJMra1308124.
- Ostrow JD, Pascolo L, Brites D, Tiribelli C. Molecular basis of bilirubin-induced neurotoxicity. Trends Mol Med. 2004;10(2):65-70. DOI: 10.1016/j.molmed.2003.12.007.
- Martinez M, García-Alonso F, Herrera E, Delgado MJ, Muñoz-Hoyos A. Oxidative stress and neonatal hyperbilirubinemia. Pediatr Res. 2003;53(5):727-32. DOI: 10.1203/01.PDR.0000064913.18075.9B.
- 20. Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci USA. 2009;106(13):5171-6. DOI: 10.1073/pnas.0813132106.
- 21. McDonagh AF, Assisi F. The ready isomerization of bilirubin IXα in aqueous solution.Photochem Photobiol. 1972;15(6):611-29. DOI: 10.1111/j.1751-1097.1972.tb06230.x.
- 22. Gourley GR. Bilirubin metabolism and kernicterus. Adv Pediatr. 1997;44:173-229.
- 23. Perlman M, Beaty B, Karn CA, Papile LA. Hyperbilirubinemia and intracranial hemorrhage in the premature infant. **Pediatrics**. 1983;71(5):601-6.
- Stevenson DK, Wong RJ. Neonatal hyperbilirubinemia: a genetic and an epigenetic story.
 Semin Perinatol. 2021;45(2):151379. DOI: 10.1016/j.semperi.2020.151379.

- Watchko JF. Identification of neonates at risk for hazardous hyperbilirubinemia: emerging clinical insights. Pediatr Clin North Am. 2009;56(3):671-87. DOI: 10.1016/j.pcl.2009.03.003.
- 26. Ahlfors CE. Measurement of unbound bilirubin: the clinical utility of the peroxidase method. **Clin Biochem**. 2002;35(1):57-63. DOI: 10.1016/S0009-9120(01)00268-4.
- 27. Mishra S, Agarwal R, Deorari AK, Paul VK. Jaundice in the newborns. Indian J Pediatr.
 2008;75(2):157-63. DOI: 10.1007/s12098-008-0027-2.
- Bhutani VK, Johnson LH, Keren R. Diagnosis and management of hyperbilirubinemia in the term neonate: for a safer first week. Pediatr Clin North Am. 2004;51(4):843-61. DOI: 10.1016/j.pcl.2004.03.009.
- Kaplan M, Hammerman C. Hyperbilirubinemia in the term newborn and the role of bilirubin-induced neurologic dysfunction (BIND). Early Hum Dev. 2005;81(1):83-90.
 DOI: 10.1016/j.earlhumdev.2004.10.010.
- 30. Sgro M, Campbell DM, Shah V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. **CMAJ**. 2006;175(6):587-90. DOI: 10.1503/cmaj.060328.
- Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med. 2001;344(8):581-90. DOI: 10.1056/NEJM200102223440807.
- 32. El-Farrash RA, Shouman BO, Bassiouny MR, Mahmoud NH. Effect of ursodeoxycholic acid on neonatal hyperbilirubinemia: A randomized controlled trial. *Pediatrics International*. 2020;62(4):456-63.
- 33. Ahmed AE, Abdelhameed MA, Eltahlawy EM, Salah MM. Ursodeoxycholic acid as an adjunct to phototherapy in neonatal jaundice: A prospective study. *J Matern Fetal Neonatal Med.* 2021;34(5):752-9.

- 34. Kumar N, Gupta P, Sethi RS, Sharma R, Narang R. Role of ursodeoxycholic acid in unconjugated hyperbilirubinemia: A randomized controlled study. *Indian J Pediatr.* 2019;86(11):1045-51.
- 35. Zarif M, Ghafoor S, Hameed A. Comparative effectiveness of UDCA and phototherapy versus phototherapy alone in neonatal jaundice. *Neonatology*. 2021;119(2):160-7.
- 36. Dikmen S, Korkmaz A, Yigit S. The impact of ursodeoxycholic acid on bilirubin metabolism and phototherapy duration in neonatal jaundice. *Eur J Pediatr.* 2020;179(9):1456-62.
- 37. Ali SM, Mohamed AH, El-Sayed MW, Eltayeb A. Effect of ursodeoxycholic acid on phototherapy duration in neonatal hyperbilirubinemia: A clinical trial. *J Perinatol.* 2018;38(7):898-904.
- 38. Zhang Y, Chen Y, Wang L, Liu Y. Ursodeoxycholic acid improves bilirubin clearance and reduces phototherapy time in term neonates. *Pediatr Res.* 2020;88(3):527-33.
- 39. Huang Y, Cheng M, Wang Q. Genetic influences on the efficacy of UDCA in neonatal hyperbilirubinemia. *Neonatal Med J.* 2019;36(1):44-51.
- 40. Mohammed S, Bashir T, Saeed H, Khan Y. The safety profile of ursodeoxycholic acid in neonatal jaundice: A cohort study. *J Trop Pediatr.* 2020;66(2):175-81.
- 41. Gholami S, Aramesh S, Taghizadeh A, Karimi A. Gastrointestinal side effects of UDCA in neonates: A retrospective analysis. *BMC Pediatr*. 2021;21(1):112-9.
- 42. Tsai MT, Tarng DC. Beyond a measure of liver function—bilirubin acts as a potential cardiovascular protector in chronic kidney disease patients. *Int J Mol Sci.* 2018;20(1):117. doi:10.3390/ijms20010117.

43. **Amin P.** Unconjugated Neonatal Hyperbilirubinemia: Complications. *The Calgary Guide* [Internet]. 2017 Sep 18

<u>ANNEXURE –I</u> INFORMED CONSENT FORM

Title of the Study: *Effect of Ursodeoxycholic Acid in Unconjugated Hyperbilirubinemia in Term Neonates Treated with Phototherapy*

Principal Investigator: Dr. Chinthapuvu Vivek
Institution: B.L.D.E. (Deemed to be University), Shri B.M. Patil Medical College Hospital and Research Centre, Vijayapura, Karnataka
Department: Paediatrics
Guide: Prof. (Dr.) R. H. Gobbur, Professor, Department of Paediatrics

Patient Information Sheet

You are being invited to participate in a research study that aims to evaluate the effect of **Ursodeoxycholic Acid (UDCA) as an adjunct to phototherapy** in the management of **unconjugated hyperbilirubinemia** in term neonates. This study is being conducted at **Shri B.M. Patil Medical College Hospital and Research Centre, Vijayapura**. Before you decide whether or not to participate, please read the following information carefully.

Purpose of the Study:

Neonatal jaundice due to **unconjugated hyperbilirubinemia** is common in newborns. Phototherapy is the standard treatment, but certain pharmacological agents like **Ursodeoxycholic Acid (UDCA)** have been studied as potential adjuncts to enhance bilirubin clearance. This study aims to determine whether UDCA administration along with phototherapy reduces bilirubin levels **more effectively** and shortens the **duration of phototherapy** and hospital stay.

Study Procedures:

If you agree to participate, your newborn will:

1. Be assigned to one of two study groups:

- **Group 1 (UDCA + Phototherapy):** Your baby will receive **oral UDCA** in addition to standard phototherapy.
- **Group 2 (Phototherapy Alone):** Your baby will receive **only phototherapy** as per standard guidelines.
- 2. Undergo **blood tests** to monitor bilirubin levels at **0**, **24**, **and 48 hours** until phototherapy is no longer required.
- 3. Have their hydration status and vital signs closely monitored during the study period.
- 4. Be observed for **any side effects**, such as vomiting, diarrhea, or feeding intolerance.

Potential Benefits:

- This study may help determine if UDCA reduces bilirubin levels more efficiently than phototherapy alone.
- Your newborn may benefit from a **shorter hospital stay** if UDCA proves effective.
- The findings may improve the management of **neonatal jaundice** in future cases.

Potential Risks and Side Effects:

- UDCA is generally well tolerated, but **mild gastrointestinal symptoms (vomiting, diarrhea)** may occur in rare cases.
- Blood sampling for bilirubin testing is **minimally invasive** but may cause **temporary discomfort** to the baby.

Confidentiality:

All personal and medical information related to your baby will be kept **strictly confidential**. Your baby's identity will not be disclosed in any reports or publications resulting from this study.

Voluntary Participation:

- Participation in this study is **completely voluntary**.
- You are free to **withdraw at any time** without affecting your baby's medical care.
- If you choose not to participate, your baby will receive **standard phototherapy** as per hospital protocol.

Contact Information:

If you have any questions regarding this study, you may contact:

- Dr. Chinthapuvu Vivek, Principal Investigator Phone: [Your Contact Number]
- Prof. (Dr.) R. H. Gobbur, Guide and Unit Chief, Department of Paediatrics Phone: • [Hospital Contact]

Consent Statement:

I, the undersigned, have read and understood the information provided in this document. I have had the opportunity to ask questions and have received satisfactory answers. I voluntarily consent for my newborn to participate in this study. I understand that I can withdraw my child from the study at any time without affecting his/her medical treatment.

Parent/Guardian Name:	
Relationship to Baby:	
Signature/Thumb Impression:	
Date:	
Investigator's Name:	_
Signature:	
Date:	



ANNEXURE -II

CASE PROFORMA

1. DEMOGRAPHIC INFORMATION

NAME: B/O

SEX:

IP NO:

ADDRESS:

CONTACT NO:

2. PATIENT INFORMATION

DATE & TIME OF DELIVERY:

ADMISSION DATE:

OBSTETRIC HISTORY:

M/H/O: PIH/Preeclampsia/Eclampsia/GDM/others

ANTENATAL STEROIDS:

MODE OF DELIVERY:

INDICATION OF DELIVERY:

DELIVERED AT: INBORN / OUTBORN

BIRTH WEIGHT:

MOTHER BLOOD GROUP:

BABY BLOOD GROUP:

3. CLINICAL INFORMATION

APGAR SCORE AT BIRTH: After 5 Min: After 10 Min: DOWNE'S SCORE AT ADMISSION: ANTHROPOMETRY: HC......cm/Length......cm/MAC......cm HR: CFT: AF: SpO2 (Right UL: Left LL:) SYSTEMIC FINDINGS: CVS: RS: CNS: PA: PRIMARY MODE OF RESPIRATORY SUPPORT:

OUTCOME :

4. INVESTIGATIONS ON ADMISSION

GRBS AT TIME OF ADMISSION:

Hb- PCV- TC- N/L- PLATELET COUNT-

BLOOD GAS ANALYSIS(if done):

PH- PCO2- PO2- HCO3- BASE DEFICIT- LACTATE-

CRP- CREATININE- Na- K- Ca-

CXR findings:

LUNG USG (if done):

2D ECHO (if done):

5. TREATMENT INFORMATION

DATE AND TIME OF UDCA ADMINISTRATION:

DOSE OF UDCA:

FREQUENCY OF UDCA:

ADVERSE EFFECTS:

WEIGHT LOSS IN THE FIRST 24 HOURS OF LIFE

(% of body weight).(dehydration)

MONITORING DETAILS:

	Day 1	Day 2	Day 3
HR			
spO2			
RR			
Tsb			
Ucb			

6. CLINICAL OUTCOME


BILIRUBIN ON ADMISSION:

BILIRUBIN ON DISCHARGE:

NUMBER OF DAYS OF NICU STAY:

DURATION OF PHOTOTHERAPY: WEIGHT LOSS ON DISCHARGE (% of body weight): DAY OF INITIATION OF EXPRESSED/DBF: DAY OF DISCHARGE FROM NICU: CLINICAL STATUS AT DISCHARGE:

<u>ANNEXURE –III</u> ETHICAL CLEARANCE CERTIFICATE




58

ANNEXURE- IV MASTER CHART

Acclauras Nama Sox 1340 Samawat Nale	 Pikm Actives - Contact surves Data & Intercloketing BRAPH mutters and Vij - 74(1)-66(2) (54(2),63(3)) pre- 	Admission debector an Achiever VI+ O Cold OVE2 COPY of STAtes Have	Total dia Estimat	internation and a SCS rition	Bith weight in Waster a social Bable is contigende 2 6 42 positive — Expension	9 FERDORFAD	44 start-fila 9	142	ədm ar c0™ si 38<)	idir milite II ir filgt : Bylli 2	of killion: CrtS 96 Karnal	75 "komel	AS-ryt Icra	nttane xt Kimil	rn Jankorperissonau A	55753,X124-004755J 13 116	45-00-LCI \$7	rate and the IN	n2: was Usb H	n Æbors, Dele med her af Dear el JOCA 1923 - 242 (Ap ril : Tradajda),	adamatas Karaento 1)	Castryawak Cryst 1 262	1Darage
2 Súltast a Feisle	962 mile: why a 60 6015 2022 10 him	1265-262 xini a 1 37 w FRC1	1978	1007	216 Cipis keil Oldashei	3	9	147	-40 <\$	33	9 ⁵ Konsi	wend	tem	Versi	2 2		112	215	12.1	112/22 2 5rg Trabats,	1 1	24	1 Daraye
1 50 Bentric Nee 1 50 States Arrais	10215 F1: (\$9900) 7015 6060 21154(0.40 51 20022 Covern source: #2157661 1161-24.3 22 61	1/42/38 Pith/h Six oxiectan Tratalisi GP3.3xth 21; proje			21 A seitar Aperika 317 A seitar Aperika	1	9	144	40<1 45<1	33 33	9º Kartai 9€ Kartai	'ivensi 'ivensi	tern tern	Vernal Vernal	4 2		7.6 16.3	18.4 20.7	112	2514214024 (Self Trabalis, 12422-2140 (Self Trabalis,	1 1	2.5 2.72	1 D 9271 pe 1 D 9271 pe
SEO Grides E Nato	2673-man (apr. 9823674-2643-54" pr.	1-38-3828 CIP312/P36 -14	LINES	21	200 Banite Eperia	,	6	16	42<0	в	06 Harnal	kest	ken	Veral	4		67	H.S	1	SE26.3-Gegen 2 Jrabala,	1 1	234	10 2010
1 3-3 448 ways Male	3025 Anada; Ed. 9623678 344 3,722m	2: 51 300 airtin 1 Sheriker	2.4	nor	278.4 seite Maseite	3	5	159	29<1	33	SE Norsi	wend	tem.	Vind	a)		7.8	21.7	115	25511 Stgfert Trababy	ı 3	248	1 Darnje
230 Ropel Finale	31152 estatenal e.g., 91662862 (3.17263.18pm	1-51-2021 GFD. (12 x 11-bre	L9CS L9C8	nce	15 C positia - A positia	3	\$	144	-24	8 19	96 Kornal 97 Kornal	'kornel	k:13	Nimal Nimal	0	21 11 152	162 84	2.9	123	112 <u>Skole gilani</u> , Inglaite,	1 1	2.5 538	1 Dacespe
1 30 rołs – Fanalo 1 30 zasamna Nalo	7682 matter valvia - 8685-889 82324,3 5an 8682 matter valvia - 96839829 14534 845 m	3-15-368 GEF : Livita Shore 3-15-368 pinita 1 Shehore	1908	rtan rtan	BEBankho Episika PECipisika Episika	,	2	149	4(<) 4(<)	8 13	SC Konsi	'kmel 'kmel	km km	'errel	4		12	81	11.1	HT 1636426111 (Traballe), 111636625111 (Traballe),	1 1	3.66	1 Darage 1 Darage
13 3-3 Any sta Farsain	Wellingeringer Wellingt Break 12 and	1944-2008 (20P* . 1 wt, 50* Nore	LAT.	1221	14 miles Ocalio	1	9	142	40 < 1	ж	99 Normal	kerel	tem	Veral		1 37	2.9	18.5	12.8	1851-1964 @igen " Ingagan;	1 1	2.7	10011
1° 3/0 Hagureen Fierdo	20022 along 96455642 5504, 1026pm	2946-2024 COF2.2 who 20pt years		1221	21 C pestita - Aregistra	3	9	144	-26	13	9 ⁵ Karnai	'kresi	hern.	Virtal	rê.	13 22	16	15.8	121	Hotzi gim if Ingigin;	1 1	265	i Darraga
12 BD can sep Fersie 13 BD can i sapilite	75455 janaka ni caya 2007 6645 40634 515 cu 2556 4 beara pikya 2005 2017 45557 2019	347-368 GSF (Twin Er Nor 347-368 GSF) and STacone	LECS	rten	22.4 seite Aproia 2.0 regise October		9	10 10	42<1 42<1	33 37	SE Konsi SE Konsi	'kensi 'kensi	ten ten	Nerral Nerral	2	22 19 - "55	83 163	15.9	12.2	175324 get not Installa. United stricts installa.	1 1	E1 29	1 Dacrage 1 Dacrage
11 ET STREAT / Fundo	AREJE STERAR 2311	FORENSIF', 1 40 We have	19:5	1021	110patha Ocalie	1	2	144	44.43		S ^A KITM	formel	1213	Wind I	4		105	17.7	N	1113124 24t not 114444,	1 1	\$	100010
15 EX conta null Finale	beganntigine: 9687-6661-2022(6.20m	10301GFL2F at mothin	city LOCS	rtan	241 Operator Aperaio	3		142	40<3	в	9º Korná	kensi	km	Virral	ρ	2 '44	162	P.I	162	1212424 Sten31 Trabala,	1)	232	10,87430
18 BD Startys In Fersile	1055 (igaran 2010-0067) 2545,938 an	560004G3F1.1-x1+214vr	1958	rten	118 Cipit ka Octobe	3	9	144	42<1	11	97 Romai	tensi	tem.	Venal			126	27	155	Balligun Tinggia,	1 1	5.18	1 Darnye
17 EC-ackin budikale 19 EC-savita kar Farsalo	SE AND SAENE "1735.0m SE AND POINT TOUGHT	9/5/08 Priving Aros 9/5/08/06 at 3/5/06/14	Del Telever	דכני דכני	26 4 meltas - A postila 2 C postila - A postila	1	8	142	41<)	23 23	9 ⁰ Котка 9 ⁰ Котка	'konel 'konel	terna Norma	Normal Normal	de Tomus ∂	12 725 13 793	102 44	17.9 25.9	164	11 (24)? Sign ' Trabata; 11 (24)? Sign ' Trabata;	1 1	5.8 3	t Daceage t Daceage
18 EO Enzymai Naio	242 April 209400 1720.4m	919203 GG1 a 1 36 a fer:	LINCS	10.0	201 Santa Aperia	i	9	14:	4(<)	в	St Konel	kenst	N'B	Versi		4)	6.6	15.5	125	H 1947- Stor, H Drahala,	(plax	24	10.82410
23 EC Crenefix Neo	NE 11,000 ERE 1998 AVE	INTRODUCTION CONTRACT STATUS	1973	TEET	26 C per 29 0 cz4 e	1	9	162	42 45	31	9º North	'kerel	tem.	Virral	SC 2		163	22	12.4	115 19497- 2 shu', Jubgani,	۱ 1	275	100/124
2 30 rapp ic i Fanalo 22 80 Status ArFanalo	(2011 olan) general MCENSS21 * 1172(7,16pm) SEE Vieweran - MCENSS21 * 146, 302(8) Sam	NONZER Preisingen ander NONZER Preisingen ander	LISCS	rten rten	22 Banitas Ornalas 26 Annitas Annaia	1	9	122	42 <1	23 33	SE Karnal SE Karnal	'kenal 'kenal	tern tern	Nortal Nortal	4 2	1 ····	U.	16.9 26.2	115	feldenit gierich bradaile. Eldenit gierich bradaile.	1	12 244	10xrap 10xrap
21 BO/ht facer Mile	ALE GRADUE TOTELAST DECEMBER OF	3-2-30(-3F).23+1 co.1/6		100	271 ABIKSI ME BORSIA	ź	9	142	40<1	33	SE Konsi	Wend	tem.	Vend		12 '51	55	152	12	11243: Stand Trabats.		24	103/10
24 ECG gell best v Fensie	PE 1 Supple SPECIE EP20.0 m	1967-2068 officiant streams	1973	таат	22 Basta Epista	3	8	162	44.43	33	9º Katal	Torrel	12'13	ilenti ^e	0		7.6	12.5	12.4	112432 \$ 4m2 Ingests;	1 1	2.5	1000926
25 340 Sunila Naio	REC ANNUE - IMPERSENCE - NEVER-John	3427-3828 GBF 1, 1 with 51 Next	L908	Cristan .	22 Cprsite O calles	3	9	144	-0<)	в	9º Kornal	kmi	kт	Yimd	86 mers 2		85	22.5	12.1	142997- SEWE Justala.	1 4	2.3	1092930
21 90 Karita na oklade 27 BCO Ratioson a Fionado	755 nakonomyjek 1962 4860 21020, film 765 chalafaprom 1627 9065 11054 Estern	10/16/2017 mindle 27 wildow 10/16/2021 scholarth ST-wildow	TAL DAL	rten	21 Cprs kn Spen ka 22 Sanstan O cast on	1	9	15: 167	42<3 42<3	13 11	SE Horsai SE Horsai	'kensi 'kensi	km km	Yernal Yernal	s a		12' 59	18.8 17.4	122 127	1 111/03: 2 Spri - Trajajia. 1 10/03: 2 Spri - Trajajia.		2.1 1.2	1 Darage 1 Darage
23 BO Rot + nin Finalo	20051 ola (gazar 1982: 1972: 2022) 7.57m	1910/03 - Tivit 2" o fors	LSCS	MOT	20C 4 pairs 4 pairs			142	44)	13	9 ⁶ Kama	krei	kera.	Virral		1 10	73	12.6	112	116 12 Signa Ingaging	, i	236	1Darage
3 80% ni ste Fende	1155 (santa), 45; \$764822 (1190), L26 ar	115000 Privit Stanker	1928	rten	25 Baeller Borske	3	5	144	38<1	57	SE Konsi	Wers	tem.	Vensi		13 157	тa	14.9	122	218 " A gerra Diabata,	ı 1	54	10araje
21 EC-Gazerro Finale 21 EO uart alto Nels	11722 Talkol Dijajej - 81670006 511730/146m 11615 ing disepter - 90036728 511730/1641 av	116.2021 Professionals ************************************	LISCS	Cutan rtan	24 Basilar Episika 226 Cpisika Episika	1	9	142	40<1 42<1	33 33	SE Konsi S ^a Konsi	'kenel 'kenel	tern tern	Nortal Nortal	4 2 74m 2		8.6 13.1	16.9 26.7	12.1	15 att değ türrür ürgeğiş, 12 att değ 10 mil 1 yakşiş,	1 1	13 13	1 Darage 1 Darage
12 EO-kens million	Silferanga yipa 960020 "AT Mill Stra	"-2.321 - tinit 2 a fat	1908	rtan	222 A anily Episita	1	9	144	46<)	B	9" Karnal 9" Karnal	kensi	km	'erral		23	16.5	E.S.	127	1220/10-2 Krr Trabala,	1 2	13	10211
11 ECopri terriferale	table the second projects BBI	THE MON GOP OF WHICH WAR	1978	7107	154 sele Asele	3	9	144	42<1	33	SE Konsi	wend	tem.	Vend	8-m	13 '67	158	1E.1	12	115 18-13: 2 In Trabats,	aning 1	2.8	1 Darnys
21 Et0 Tejaz mee Nale	14624 (c), \$66000 SEC 8862 327-54-52 (c) (on	"-2-2004 string \$35-4 large	21.4	ncer	21.4 nopelive – Arregative	3	\$	15:	-6<1	32	SE Komai	'kornel	k:13	limi ^r		2 101	5.8	H.I	65	5"26"12" 3" lon 'linghgåg;	1 1	2	1 Daceage
25 EXX Viges not Fanale 25 EXX Viges not Fanale	1993) ola (1994) - XOSONE 107,54 (1997) 1992 Takwa ay, Ar., 1904-207,54 (1997)	120303 GP1.141 within: 120303 GP1.0141 (Climbelin	L9C8	rtan	185 Operator Encaritor 11 OFISIAN Orașelan	3	9	144	42<1 43<1	19 19	SE Kornal SE Kornal	Werel Werel	NTB NTB	Normal Normal	0	2 '65 12 '51	11.3 11.3	a.s '5	148	f 1 <u>3-37-6 den 1</u> Trabala; f 13-37- Starf Trabala;	1 1	537 210	1 Dacept 1 Dacept
2" ED Stal Bar Nile	TREE DALARY SIGNAL AND AN	Diblick of a table of	19:5	ator	25 Basta Epista	í		162	44.43	11	99 Kartai	Veral	ten	Vertel		4 14		14.5	112	the interest of the second second	1 1	247	100/10
23 EO Kantra reformio	1746 Talici 5 spc 90039668 <u>212282-1130 pr</u>	13/10/08/0/F2.25* 3:3** km	LSCS	rten	2/46 C pes ika 🛛 A pes ika	3	9	14:	41<]	11	9 ⁶ Каты	'keral	hem.	imi.		ti '67	-0	167	15.6	11 11/23 & dr Irgigit;	1 1	22	10 areas
19 30 Namen Male	1762 Fight 1984 1985 1987 1987 1987	19/5/00/GF1.12/a Place	LISCS	2011	DE Basilie - Epissia	3	9	147	42<) 4)4	87 87	9€ Konsi	Actal	tern	'erral		(; ·) 1: ·2)	10.5 87	15.8 15.8	128	11415/32-2 Kri Trabala.	1 1	2.8	10x-age
C ET Teter yal (Fersie C ET Swit kursikale	2012) Algerichten Britstelig allter 2012) Algericht Referen Britstelig allter	TO GRADER GRAD TO TATE STOLE TO GRADER WITH A TO STAN YOR	1925	דוכני דוכני	25 Baselue - Aportos 2 Baselue - Abaselue	1		144 140	44	57 33	SE CENTRE SE NUTION	Worki Worki	127B	Vernal Vernal	4 2		87	21.5	118	17.50/282 \$100 11936316, 11.51/282 \$100 11936316,	1 1	2.7 2.9	1 Darapa 1 Darapa
62 30 Sunar malo	1000 (Antar 6000000 1122 @10to	1/02/22 - Tinto State and	1908	nch:0	Di Banite Eperita	i		142	424	в	96 Kornai	kent	km	Yernel	4		167	H2	154	CHIORS 3 Im Trabala,	, j	12	10,8210
d BOGnining We	92 Ayran - 399000 Pros 1460	1/5/805 (GP2 2 vi 1 5) van	2.48	Sitan.	DIA seite Aseite	3	9	144	44	13	96 Normal	tend	tem.	Vensi	а		117	18.5	153	1 1 190105 <u>2</u> Der Diglight,	ı 1	5.2	1 Darage
41 340 Suvasit i Nale 45 340 sasitalia i Nale	111 in Aspan 1982-332 2012 galan 111 in an 111 1983 1983 1993 2012 galam	105-062 (257 with 39 within 105-062 (267 v. 1 with 35 none	LISCS	1007 1007	23 4 zeitze Apestia	3	9	129 142	4646 2446	22	96 Korsa 96 Korsa	'konel 'konel	F5.13	Normal Normal	6	1* *** 11 *\$7	III.	17.8 18.5	144	1: 20065 3. 1an . Irgagas;	1 1	12 17	1 Darage
43 50 Savia Maio 43 50 Savia Fernaio	11 Agente 983-174 2012 (6.56) 081 1040 110202 1422 63101	2/7-202 data 1 9/7-2100	1903	TICE	216 Apostvo Apostio 282 OF salve - O costvo	1	2	144	20	10 12	SE KOTSA SE KOTSA	WITE!	km km	Yernel		1 24	12	18.9 18.4	124	1529065 \$100 (11)3938; 3119985 \$100 (11)3938;	1 1	2.7	10seau 10seau
C ET Eugentende	HEIDERSELEN HATERAL AND	209-2021-0392-1 white Wate	LINE	1221	28.4 perter Aperter	1	9	144	42-5	27	SE Normi	Verel	tern.	Winel	4	2 '2'	84	16	115	12 mmillig lipe, . Installit,	1 1	1.6	10011
630 sur m Finski	m. fürm entern min Billin	2014/02 string 37 wass	214	1001	114 anitas Eposito	3	9	16	126	12	SE Korsai	'krrel	tem.	Virral	4		11/2	17.6	12.2	() 1210235 J. Im Tradaila;	aning 1	2.8	10xrap
6 90 stadate Née 51 So scort - Fersie	6210.0000 36835 3623.0000 8216.0000 96068 3623.000	205082 Frinds 26 a Mar SSUES GP (1981) Note	LISCS	זונני זונני	Dicusia Alania Dicusia Entria	,	6	142	44	17 33	66 Karsai 66 Karsai	Wend	ten ten	Versi Versi	a	14 "23 15 "2"	87 23	IES N.9	124	1120005 2 Km Trabala, 1150025 2 Km Trabala,	1	2.9 2.7	10x110 10x110
At clavitole	REMARK MEMORINAL AND A TON	CARE OF LATE OF	Land	- 546	Ethagach ge				1.4	м	2 1010		14.11		4	N SOAS	10	11.5	104	and finit thinks	· · · ·		i nacije
1304an Fimalo	99222 (assue 96239721 12224 (99pm	232-288 GF2,282 x t annie	L908	rtan	21Banite Ocalie	3	9	144	42<)	в	SE Kornai	kral	kт	Yimal		12 12	\$2	12.6	111	51	1	23	1 Daceage
2 30 Kator Fensle 1 307 Trent Fensle	279 Material VI, 9489429 (1942) Spri 1879 Material VI, 9623625 21943 Day	7-48-302 GF1,1,39 verviere 7-44-303 57 van signiji van	LISCS	1007 TCC	10 prsite October 21 Baselize Epoche	1	9	142 144	42<1	11 11	9º Kansi 9º Kansi	'kensi 'kensi	ken ken	Versi Versi	4	11 11: 11 13:1	7.8 10.5	16.7 16.5	11	27	1 1	5.8 2	1 Darage 1 Darage
(EOEnavatrikia	SEEBolenver, VE WEDDIGE ESTELLISEN	1-36-363 similart Sive som	1975	1227	12 Cateria Aregena	1		142	44	22	Se Karnal	kersi	1cm	Viral		1 51	112	15.5	12.6	11		14	10.0010
5 30 Tosseini Female	2017 Tabel 9 apr. (7039081 "XY2UCI6m	1-21-2020 Gapiti Silver: Ver:	LSCS	1000	20perite Aperic	,	9	144	+2<)	в	9 ^o Komai	kensi	K'B	Virral	0	1 23	\$3	174	12.5	12	1)	3	10.0000
1500ereth Pende	2423 tu sval 1939/965 27/20326jn	SHE JEE PYNNISE A NKE	1973	rten	21 A seiter Erreptio	3	9	16	42<1	33	SC North	werel	1273	Vernal		u –	6.9	12.5	12.5	11	1 3	2.5	100/126
7 EO Enzenañ Nais 8 30 maio - Fanalo	Millicher Agens Weinsteil 2012(1206pn Willicher Agens Willicher 1997)	17-08-0008 CDAT with Your Vane 13-08-0008 CDFR. 2 with 40 Vane	LISCS LISCS	rten	22 Cprs No O cashee 25 Ban Bay Epresia	1	9	142 148	40<1 44<1	11 13	SE Kornal SF Kornal	'krai	tem Iem	Normal Normal		11 '21 12 '13	2.3 6.6	16.5 12.9	122 114	12 11	1 1	12 24	10xrap 10xrap
1303ariji Mile	STRUCTURE OF A STRUCTURE STRUCTURE OF A STRUCTURE O	13-15 JON - right Star Wee	1978	100	14 C pra ke E pra ke	,		16	42 < 3	11	99 Kansi	tend	ten	Vend	a)		11.5	28	15	11	. í	21	103/10
10 3-0 December Wele	10210 to H1 bogel 96103350 33730,4 %en	ERST-2020 (SEP 1.1 with STAINE	2/4	TICE	16 Basta Ocate	3	9	141	42<1	33	9 ¹ Kattel	arrel	127B	Virtal	a 1		124	15.9	145	122	1	5.6	1000978
 EO, yell Rucq Female 30 Akit yana Female 	1622 claps 97196212 232201.46m 1022 claps 8020636 23220.44m	40.808 Prinkin Stanker 40.803 GER 2 vin Skuncterik	L9C8	rtan 1997	22 Blasiliko Epistoko 2015 Alasiliko Epistoko	3	9	144	-2<) ==<)	13 13	9º Kornal 9º Kornal	'krnel 'krnel	N/13 N/13	Normal Normal	2	-1 93 	69 67	H.7 19.7	11 112	11 31	3	12 13	10scap 10scap
12 SO SAN ANYA PRIMA 13 SO Watthe Millio	101223 3156401 - 40039106 26720(3-491 252023104 341:4 74) - 96234026 26720(3-691	PERSONAL STATES OF A STATE OF A	EJELE E	ntrin.	25 C Faller O Parts	,	2	102	46<1	11 26	9º Kartai	Acres .	12.11	Yurnal	4		117	12.1	142	11	,	2.3	100/10
11 3/3 Aard Note	26675 Den, dinne. 2002 Steft 227248-30en	Tablaics GPT JPT 11 Olychydri	TTT CLOCS	1228	25 C Fail e Eposte	3		14!	11 (1)	17	SE Harna	'keral	hern.	Virral		12 - 55	87	16.1	12.2	11	;	2/4	1 Darage
15 EX pec a sair Male	2010 Talkri V nati 7519-000 2020/2.16 m	SOFUL ALC MAINT FINIT SECOND	LSCS	1338	32 C Pail an Apestic	3	9	16	42<)	в	9º Kamai	'kensi	km	Yimd	2	-62	162	-7	121	121	3	29	1 Discrept
19 EO Fijana (Fersie 17 ET F10 au teñerale	2015 Ayeur 760068 2020U.Sen 1624 Ayeur 762059 39942an	Scholick SIP1. Lot 1 State Protect 21 There	L975	rten Mar	35 AB regime All sellar 2015 Strettan All sellar	1	9	144	45<1	33 33	SE Konsi SP Konsi	Wenel Wenel	1273 1273	Norther Northern Nort	2	17 144 14 164	114	17.6 17.8	164	112	1	2.9 2.6	1 Darage 1 Darage
18 EO raxone Nac	DE ANUL SERVER READ	56-2821 GEF . Livin Strikers	1908	1331	211 Casho Ocalio	3		111	4(4)	B	9 ^o Kona	kral	NTI N	Yind		14 24	7.3	12.9	12.3	17	, i	2.6	108/10
10 EC-ripys perilikile	1957 Yorny 1.454 994539275 (\$155,7 Gam	SECTOR - river 25er Ware	3.4	m	Diffesin Ocale	3	5	16	42<1	13	99 Konsi	tend	tem	Vend	4 7	15 21-	15.5	25.8	224	U 4	;	5.8	1 Darny
21 ECO-Storm of Note 21 ECO-state vite Note	1513 Minthe val Viji 780317883 506 Ja 4 58m S185 Announ – 78030883 ********	SHOULD COPTLINE STATE 9/4/2010 COPTLINE STATE	LSCS	7007 7007	Di Anelas Aparia 216 Alexas - Alexan	3	9	144	42<] +(<)	8 19	96 Korsa 97 Korsa	'kensi 'kensi	terna Iscra	Nortal Nortal	4	15 '25	82 167	14.5 16.5	124 158	31 122	1	12 15	t Darry t Darry
2° EXDeunia vita Male 12 EXD-Ea ya a zi Famale	SEE ANTON REPORT TOUGHD	9/4/08/CEF1.1vitr/5/forc 9/5/08/CEF1.1vitr/5/forc	LSCS	rten	216 dējostvo - 28 metro 1 Cipistro - O ciniko	1	9	144	42<0	8 5	9º Koma 9€ Komai	'kmel 'kmel	N/18	'Arrial 'Arrial		a 10	117 53	16.5 12	118	112	1	2.5 2.8	10seau 10seau
23 ED vis dreid (Persie	3834 AMELIA 994848405 "4375U15881	BUTRATED PHYTHAT STAF WATE	2/4	1227	21 Bauta Epurka	1	9	10	35<1	37	SE NUTSI	'arrel	1273	Vertel	4	2 17	1.2	N.5	112	21	í	1.5	100/10
21 BO Rarus Heffendo	2251 beginnet (stage - 2011 21311 - 1422) (7. 15pm	STADE States	L9CS	rets:	2°8 xalao A8 xalao	3	9	141	+2<1	11	SE Karnai	'krrel	tem	'imai	4		29	17.5	12	н	1	2.8	10xrip
25 30 Pooja Famalo 23 80-Seeta aitt Fensile	482 Talker 9, mag - 6682 9674 192209, 9 419 internation, 1, 9611 4666 19220, 340	000000 Preisin Overland 900000-500 alt die Vere	LISCS	rt:n ror	32 Kanilas Aperia 282 Alijoni ne Ministar	3	9	142 142	424]	2	GE Hornal 97 Hornal	'kensi 'kensi	ken ten	Nortal Nortal		23 13 - 23	1.1	17	128	32	2	21	1 Darrage 1 Darrage
2 30 netsted Fende	Statistics of a second statistic statistics	SECURATION AT AN ARE	12.5	rten	11-Spellar Aperte	, i	8	144	40<1	л Н	9º KITSI 9º KITSI	Tornel	1211	Winal		15 5	94	12.5	128	114	1	2.9	104719
31 EO Engrastr Fondo	SCO : Haji Agas. 90/HESSE EST26. Sen	425-2828 Printed Star Marc	L9C8	rtan	20 Carsino Apertic	3		142	<)	в	SE Kornal	krai	km	Virnel	72	12)	123	12.9	125	27	3	2.8	10.000
2) BT 9 pipelion i Famile	403 yesarci 6523650 24726630 m	127-308 GS5: A 1 36A WHIT	1908	ation	21.4 epil w Eperio	1	9	142	42<1	F	9€ Каты	kens l	K (0	Versi		4	15.1	H.I	127	12	•	12	10xmp
21 ECO data i milite 21 ECO Fast a sa Farada	TELEVISION OF WEEDERST PERSONNER INFORMATION PERSONNERS PERSONNERS	101.000 (3P : 12 - 2 - 14) 108-000 - 1101 2 - 2 - 200	L9CS	1007 1007	22.6 mpt w Propilika 22.8 mpt w Exercica	3	9	144	42<1	8 8	9º Karsa 9º Karsa	'kend 'kend	tem tem	Versel Versel	a .		7.5 1.9	5	51 124	25 1 E	1	225	1 D 921 12 1 D 921 12
S2E0296* coFinale	IEC Bapsed : sr 989 800 20120 12 Pan	1009-2009 GGAT and SFA fact	LSCS	1338	28 Carsing Electric	,	6	14:	+2<)		96 Komai	wers!	N'H	'imal	4	12 3	11.3	.6	14.2	11	,	12	10,000
11 EO Euromañensia	INCERTATION CONTRACTOR	TO CONTRACT SPECIES AT MICE	L9:5	таат	224 peter Oceller	3	9	144	46<1	33	9 ⁰ Karnal	Wenel	tem.	Vintel	4	12 151	11/2	P.4	142	11	1	2	1 Darage
21 BO-7x7 + pea Fenale 25 BO-ania + nyai Fenale	IEEE Indication V): IRC239284 23/1254 ESten HEEE Indication VI: IRC239284 23/1254 ESten	HHURE CEPTURE STREET	EAC LOCA	1221 1271	22 Cprsite Eperate 22 Cprsite October	1	9	142	48<1	11 12	SE Kornal SF Kornal	'lornel 'lornel	ten ken	Normal Normal	50 Z	12 763	124	ies HJ	12.4 11.6	112 12	1	12 2.1	i Davaga i Davaga
21 ECurits regularisation 23 3-0 norgan Fersile	1953 bigavecijaji - 9652869 21920 April 1953 osat cagji - 9558685 - 1996,000	15.000 Coll river 2 Arr	LISCE	1007	22 Cprsxs Octobe 33 Cprsxs Sprsxs	3	9	144	42<1	13	9º Karna 9º Karnai	'kensi	ten	Namel Namel		12 22	11.3	14.1	15	12	1	21	1 Darage 1 Darage
27 343 Abit ways Fansle	nder Stehten Generation vier bedienig unter	"Realized GIP" Line to Share	19:5	таст	254 Cipisites - Aposites	3	9	162	44	33	9 ¹ Katsi	arrel	1273	limi/	o	11 '03	8.	123	121	31	ĵ	2.5	1032936
39 EC: Vistan is Naic	1993 ku alog v 31 7789-402 831 395-861	1109-2021 COP1_1 who Sinker:	L9C8	nth:	Hit A server A possible	3	9	144	-2<)	в	9 ⁵ Komai	'kornel	k:n	Yimal		2 '02	62	12.6	1:1	31	3	3	1 Darage
31 ED-Studi che Fende KI ED-Studio fun Nate	19413 Mullist tal V) - 99113 XMC2 2122 (U1.95m) 19623 strappi, «Lyte - 96613 2742 2122 (Uppi	126-363 GEF (1 vin STROT) 10-5-200 striket Sike Vine	L908 L905	13.07 rtzn	25 C pisika - A pisika 32 C pisika - A pisika	3	9	142		33	SE Komei SP Komei	'kensi 'kensi	krii krii	Yernel Yernel	4	12 12	162	18.5 18	11	101 102	1	57	10x/spi 10x/spi
it 3/3/4/19. Farsie	2000 m. gay and an and a state of the state	16002 Whiat Styron	19.5	1020	25.4 mellar Aparita	3		140	4245	2	SE Karsa	Wengi	12 Th	Vertal Vertal		11 102	12	12.9	10	36	1	2.5	102/10
@ 50 Kitwi i Fersie	SCE AND TO THE REAL PROPERTY OF STATE	trisation mining i diversione	1.15	100	PETroixe Aprilia	3	9	144	424	33	96 Romai	werst	tem	Versi		19 153	112	17.9	12.2	13 5	1	2.5	1 Darage
	1991 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1	105-302 (3F) (1 v) (5 van 105-302 (3S) v 1 (5 v van	LISCE	7667 7667	26 A seiter - O seiter 24 A seiter - Epos Ja	1	9	14C 144	424	33	56 Karsa 56 Karsa	Wend Wend	tem tem	North North	4	11 '57 14 '51	8.2 18.5	18.4 17	12	11 12	1	5.6 2.4	10x1p 10x1p
OEDSnywinNie # 30.0cm Nie	201 (gen \$48-36" AT 2 graph	105-025 GS7 a 1 35 a mit		1007	25 C praixe Consider	,	9	140	424	11	SE Ronal	and a	ten.	Versi		1 - 51 12 - 12 -	ca, Ir	18.1	121	11	1	24 54	10kmp
d ED Ingalina H 30 Andii Nie K 30 Panee: Nie									44	F	44.44							2222					10.830
et 30 Ander Nee 6 30 Parker: Nee 6 ED Spanne Nee	Sit banneteine Wilficht 17.75 6 High	99202 aini a di Alive Kar	1908	11.01	J14ania 23ania	3	8	144		24	St Konel	kensi	K.B	'imal		12 123	117	K2	125	T 1	,	3	
44 30 Abrilla - Nile 45 30 Partner: Nile 45 EO Sousime Nile 47 EO Alystic Fanile	Sil kepweichen William I.S. Stig Migen 450 kepweichen William Milliam I.S. Stig Migen	200302 minia J 40m Mat	1908	13.02	25 Banka ABanka	3	9	147	425	11	SE Normal	kensi	1470	Yerrel	4	12 12	\$7	H.7	128	11	3	3 17	10,000
et 30 Ander Nee 6 30 Parker: Nee 6 ED Spanne Nee	Sit banneteine Wilficht 17.75 6 High					3 3 3	9 9 9			5 13 13 13 13 14 14 14 14 14 14 14 14 14 14 14 14 14					a a a	12 12 12		R2 H7 H5 12			נ נ נ	3 17 288 17	

ANNEXURE -- V

PLAGARISM REPORT



Submission ID trn:oid:::3618:87489841

A Flag is not necessarily an indicator of a problem. However, we'd recommend you focus your attention there for further review.